

AWARD NUMBER: W81XWH-13-2-0038

TITLE: Effects of Simulated Pathophysiology on the Performance of a Decision Support Medical Monitoring System for Early Detection of Hemodynamic Decompensation in Humans

PRINCIPAL INVESTIGATOR: Michael Joyner, M.D.

CONTRACTING ORGANIZATION:
Mayo Clinic

Rochester, MN 55905-002

REPORT DATE: February 2017

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE February 2017		2. REPORT TYPE FINAL		3. DATES COVERED 15 Sep 2013 - 14 Nov 2016	
4. TITLE AND SUBTITLE Effects of Simulated Pathophysiology on the Performance of a Decision Support Medical Monitoring System for Early Detection of Hemodynamic Decompensation in Humans				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-2-0038	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Michael Joyner, M.D. E-Mail: Jovner.Michael@mavo.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mayo Clinic 200 First Street SW Rochester, MN 55905				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT A high fraction of both battlefield and civilian trauma deaths are caused by hemorrhage and subsequent cardiovascular collapse. It is estimated that ~85% of such deaths are potentially preventable with adequate detection and intervention. However, early detection of hemorrhage and proper intervention is confounded by physiological compensatory mechanisms that can keep blood pressure and heart rate in or near normal range during blood loss of up to 30% of total blood volume. These mechanisms limit the ability of care providers to detect the imminent risk of life threatening cardiovascular collapse with traditional vital signs. In this context, machine learning algorithms developed by the U.S. Army Institute of Surgical Research, using hemorrhage simulated by lower body negative pressure, have shown significant promise in detecting subtle changes in vital signs and estimating changes in cardiac output and blood volume. These tools are currently being validated via collaborative research between the Mayo Clinic Department of Anesthesiology and the U.S. Army Institute of Surgical Research along with several industry partners. In this context, the goal of this application is to extend the pre-clinical validation of the U.S. Army Institute of Surgical Research decision support algorithm for blood loss to incorporate simulated pathophysiological conditions likely to be encountered during combat casualty care. These conditions include: 1) mild hypoxia to simulate altitude or pulmonary/chest wall injury, 2) epinephrine infusions to simulate hyperdynamic circulatory response to stress, 3) blood loss and resuscitation with hypertonic saline, and 4) endotoxin administration to simulate the onset of sepsis. Using these approaches, and leveraging the skills of the strong collaborative team, we will be in a position to further refine and validate the decision support algorithm for blood loss during concurrent pathophysiological conditions likely to be encountered on the battlefield.					
15. SUBJECT TERMS Blood Loss; decision support; resuscitation					
16. SECURITY CLASSIFICATION OF: U			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction	4
Keywords	5
Body.....	5
Key Research Accomplishments.....	5
Reportable Outcomes.....	8
Conclusion	11
References	12
Participants	16
Appendices	20

Introduction

This report details results over the entire research period of a study entitled “Effects of Simulated Pathophysiology on the Performance of a Decision Support Medical Monitoring System for Early Detection of Hemodynamic Decompensation in Humans.” This monitoring technology was developed based on a simulated hemorrhage model using LBNP. Over the last three years we have published four papers related to the use of LBNP as a non-invasive surrogate to study the hemodynamic effects of actual blood loss and the physiological responses to these maneuvers.

White blood cell concentrations during lower body negative pressure and blood loss in humans. Van Helmond N, Johnson BD, Curry TB, Cap AP, Convertino VA, Joyner MJ. Exp Physiol. 2016 Oct 1;101(10):1265-1275.

Cerebral blood velocity regulation during progressive blood loss compared with lower body negative pressure in humans. Richards CA, Johnson BD, Harvey RE, Convertino VA, Joyner MJ, Barnes JN. J Appl Physiol 2015 Sep 15; 9119(6):677-85.

Coagulation Changes during Lower Body Negative Pressure and Blood Loss In Humans. Van Helmond N, Johnson BD, Curry TB, Cap AP, Convertino VA, Joyner MJ. Am J Physiol Heart Circ. Physiol. 2015 Nov;309(9):H1591-7.

Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses. Johnson BD, van Helmond N, Curry TB, van Buskirk CM, Convertino VA, Joyner MJ. J Appl Physiol 2014 Jul 15;117(2):131-41.

These papers were published in Experimental Physiology, Journal of Applied Physiology, and American Journal of Physiology-Heart and Circulatory Physiology and are included as an additional attachment to this report.

Keywords

Trauma, coagulation, central venous pressure, stroke volume, pulse pressure, catecholamines, heart rate, mean arterial pressure, cerebral blood velocity, leukocytes.

Body, Key research accomplishments & reportable outcomes

The abstracts from these papers summarize key accomplishments and outcomes.

The purpose of this study was to compare hemodynamic and blood analyte responses to reduced central venous pressure (CVP) and pulse pressure (PP) elicited during graded lower body negative pressure (LBNP) to those observed during graded blood loss (BL) in conscious humans. We hypothesized that the stimulus-response relationships of CVP and PP to hemodynamic responses during LBNP would mimic those observed during BL. We assessed CVP, PP, heart rate, mean arterial pressure (MAP), and other hemodynamic markers in 12 men during LBNP and BL. Blood samples were obtained for analysis of catecholamines, hematocrit, hemoglobin, arginine vasopressin, and blood gases. LBNP consisted of 5-min stages at 0, 15, 30, and 45 mmHg of suction. BL consisted of 5 min at baseline and following three stages of 333 ml of hemorrhage (1,000 ml total). Individual $r(2)$ values and linear regression slopes were calculated to determine whether the stimulus (CVP and PP)-hemodynamic response trajectories were similar between protocols. The CVP-MAP trajectory was the only CVP-response slope that was statistically different during LBNP compared with BL (0.93 ± 0.27 vs. 0.13 ± 0.26 ; $P = 0.037$). The PP-heart rate trajectory was the only PP-response slope that was statistically different during LBNP compared with BL (-1.85 ± 0.45 vs. -0.46 ± 0.27 ; $P = 0.024$). Norepinephrine, hematocrit, and hemoglobin were all lower at termination in the BL protocol compared with LBNP ($P < 0.05$). Consistent with our hypothesis, LBNP mimics the hemodynamic stimulus-response trajectories observed during BL across a significant range of CVP in humans.

Lower body negative pressure (LBNP) is often used to simulate blood loss in humans. It is unknown if cerebral blood flow responses to actual blood loss are analogous to simulated blood loss during LBNP. Nine healthy men were studied at baseline, during 3 levels of LBNP (5-min at -15, -30, -45 mmHg), and during 3 levels of blood loss (333, 667, 1000 ml). LBNP and blood loss conditions were randomized. Intra-arterial mean arterial pressure (MAP) was similar during LBNP compared with blood loss ($p \geq 0.42$). Central venous pressure (CVP; 2.8 ± 0.7 vs. 4.0 ± 0.8 , 1.2 ± 0.6 vs. 3.5 ± 0.8 , 0.2 ± 0.9 vs. 2.1 ± 0.9 mmHg for level 1, 2, and 3; $p \leq 0.003$) and stroke volume (71 ± 4 vs. 80 ± 3 , 60 ± 3 vs. 74 ± 3 , 51 ± 2 vs. 68 ± 4 ml for level 1, 2, and 3; $p \leq 0.002$) were lower during LBNP compared with blood loss. Despite differences in CVP, middle cerebral artery velocity (MCAv) and cerebrovascular conductance (CVC) were similar between LBNP and blood loss at each level (MCAv at level 3: 62 ± 6 vs. 66 ± 5 cm/s; $p = 0.37$; CVC at level 3: 0.72 ± 0.05 vs. 0.73 ± 0.05 cm/s/mmHg; $p = 0.53$). While the slope of the relationship between MAP and MCAv was slightly different between LBNP and blood loss (LBNP: $.41 \pm 0.03$ cm/s/mmHg vs. Blood Loss: 0.66 ± 0.04 cm/s/mmHg; $P = 0.05$), time domain gain between MAP and MCAv at maximal LBNP/blood loss ($P = 0.23$), and low frequency MAP-mean MCAv transfer function coherence, gain and phase were similar ($P \geq 0.10$). Our results suggest that cerebral hemodynamic responses to LBNP to -45 mmHg and blood loss up to 1000 ml follow a similar trajectory, and the relationship between arterial pressure and cerebral blood velocity are not altered from baseline under these conditions.

We tested the hypothesis that markers of coagulation activation are greater during lower body negative pressure (LBNP) than those obtained during blood loss (BL). We assessed coagulation using both standard clinical tests and thrombelastography in 12 men who performed a LBNP and BL protocol in a randomized order. LBNP consisted of 5-minute stages at 0, -15, -30, and -45 mmHg of suction. BL included 5 minutes at baseline and following three stages of 333 mL of blood removal

(up to 1000 mL total). Arterial blood draws were performed at baseline and after the last stage of each protocol. We found that LBNP to -45mmHg is a greater central hypovolemic stimulus vs. BL, therefore the coagulation markers were plotted against central venous pressure (CVP) to obtain stimulus- response relationships using the linear regression line slopes for both protocols. Paired t- tests were used to determine if the slopes of these regression lines fell on similar trajectories for each protocol.

Mean regression line slopes for coagulation markers vs. CVP fell on similar trajectories during both protocols, except for TEG α° angle (-0.42 ± 0.96 during LBNP vs. $-2.41 \pm 1.13^\circ/\text{mmHg}$ during BL, $p < 0.05$). During both LBNP and BL coagulation was accelerated as evidenced by shortened R-times (LBNP 9.9 ± 2.4 to 6.2 ± 1.1 BL 8.7 ± 1.3 to 6.4 ± 0.4 , both $p < 0.05$). Our results indicate that LBNP models the general changes in coagulation markers observed during BL.

Hypovolaemia has been associated with an immune response that might be secondary to sympathoexcitation. We tested the hypothesis that simulated hypovolaemia using lower body negative pressure (LBNP) and real hypovolaemia induced via experimental blood loss (BL) cause similar increases in the white blood cell concentration ([WBC]). We measured [WBC] and catecholamine concentrations in 12 men who underwent an LBNP and a BL protocol in a randomized order. We compared 45 mmHg of LBNP with 1000 ml of BL; therefore, [WBC] and catecholamine concentrations were plotted against central venous pressure to obtain stimulus-response relationships using the linear regression line slopes for both protocols. Mean regression line slopes were similar for total [WBC] (LBNP $183 \pm 4 \mu\text{l}^{-1} \text{ mmHg}^{-1}$ versus BL $155 \pm 109 \mu\text{l}^{-1} \text{ mmHg}^{-1}$, $P = 0.15$), neutrophils (LBNP $110 \pm 2 \mu\text{l}^{-1} \text{ mmHg}^{-1}$ versus BL $96 \pm 72 \mu\text{l}^{-1} \text{ mmHg}^{-1}$, $P = 0.15$) and lymphocytes (LBNP $65 \pm 21 \mu\text{l}^{-1} \text{ mmHg}^{-1}$ versus BL $59 \pm 38 \mu\text{l}^{-1} \text{ mmHg}^{-1}$, $P = 0.90$). Mean regression line slopes for adrenaline were similar (LBNP $15 \pm 5 \text{ pg ml}^{-1} \text{ mmHg}^{-1}$ versus BL $16 \pm 4 \text{ pg ml}^{-1} \text{ mmHg}^{-1}$, $P = 0.84$) and were steeper during LBNP for noradrenaline (LBNP $28 \pm 6 \text{ pg ml}^{-1} \text{ mmHg}^{-1}$ versus BL $9 \pm 6 \text{ pg ml}^{-1} \text{ mmHg}^{-1}$, $P = 0.01$). These data indicate that central hypovolaemia elicits a relative leucocytosis with a predominantly neutrophil-based response. Additionally, our results indicate that LBNP models the stimulus-response relationship between central venous pressure and [WBC] observed during BL.

Next Steps

Additional data analysis and manuscript preparation/submission is in process related to our second and third studies on the effects of hypoxia and systemic epinephrine infusion respectively on responses to simulated blood loss is underway. Data collection for both studies has been completed. We are currently preparing/submitting manuscripts related to the hemodynamics, cerebral blood flow, cardiac baroreflex sensitivity, and hormonal responses associated with our study on the effects of hypoxia on the decision support medical monitoring system and related physiological variables and responses.

Reportable Outcomes

We will focus on new unreported/published data from the systemic epinephrine trials since the data from the hypoxia trials have been reported in the previous annual report. The rationale for this study was that combat injuries frequently evoke a sympathoexcitatory response and we wanted to mimic this response in the laboratory. As such, testing the decision support medical monitoring system and related physiological variables during these conditions was an important step for the continued development of the algorithm and understanding of hemodynamic decompensation during battlefield or trauma situations.

We have completed data analysis on 10 subjects. Data from these subjects show that during systemic epinephrine infusion total time to presyncope (figure 1) was similar to saline infusion ($P>0.05$). Examination of hemodynamic variables, showed mean blood pressure (figure 2) and total peripheral resistance (figure 6) were lower during LBNP with epinephrine vs. saline infusion ($p<0.05$). Heart rate (figure 3) and pulse pressure (figure 5) were higher during LBNP with epinephrine infusion vs. saline ($p<0.05$), while the decrease in stroke volume (figure 4) had a similar trajectory.

Figure 1. Time to tolerance during epinephrine and saline infusion




Figure 2. Mean blood pressure trajectories during LBNP with epinephrine and saline infusion




Figure 3. Heart rate trajectories during LBNP with epinephrine and saline infusion




Figure 4. Heart rate trajectories during LBNP with epinephrine and saline infusion




Figure 5. Pulse pressure trajectories during LBNP with epinephrine and saline infusion






Figure 6. Total peripheral resistance trajectories during LBNP with epinephrine and saline infusion



In addition, we assessed cerebral blood flow by insonating the middle cerebral artery and found no differences in middle cerebral artery velocity trajectories during LBNP with epinephrine infusion vs. saline infusion (figure 7).

Figure 7. Middle cerebral artery velocity trajectories during LBNP with epinephrine and saline infusion



Conclusion

The last three years have been highly successful and we have completed key manuscripts related to the main aims of the funding cycle including publication of four papers in highly visible journals. Additional peer-reviewed manuscripts are in the process of being submitted on the influences of hypoxia and systemic epinephrine infusion on responses to simulated blood loss. These papers represent an important step forward in the understanding of hemodynamic decompensation during battlefield or trauma situations and the continued development of the Army's compensatory reserve index algorithm.

References

Published and in preparation manuscripts:

- Johnson BD, van Helmond N, Curry TB, van Buskirk CM, Convertino VA, & Joyner MJ. Reductions in Central Venous Pressure by Lower Body Negative Pressure or Blood Loss Elicit Similar Hemodynamic Responses. *Journal of Applied Physiology*, 117(2):131-141, 2014. doi:10.1152/japplphysiol.00070.2014.
- Rickards CA, Johnson BD, Harvey RE, Convertino VA, Joyner MJ, & Barnes JN. Cerebral Blood Flow Regulation during Progressive Blood Loss Compared to Lower Body Negative Pressure in Humans. *Journal of Applied Physiology*, 119(6): 677-685, 2015. doi:10.1152/japplphysiol.00127.2015
- van Helmond N, Johnson BD, Curry TB, Convertino VA, & Joyner MJ. Coagulation Changes during Lower Body Negative Pressure and Blood Loss in Humans. *American Journal of Physiology-Heart and Circulatory Physiology*, 309(9): 1591-1597, 2015. doi:10.1152/ajpheart.00435.2015.
- van Helmond N, Johnson BD, Curry TB, Cap AP, Convertino VA, & Joyner MJ. White blood cell concentrations during lower body negative pressure and blood loss in humans. *Experimental Physiology*, 101(10):1265-1275, 2016. doi:10.1113/EP085952
- van Helmond N, Johnson BD, Holbein WW, Petersen-Jones H.G., Curry TB, Convertino VA, Joyner MJ. Effect of acute hypoxia on cerebral blood flow regulation during lower body negative pressure, in preparation

- Baker SE, van Helmond N, Scruggs Z, Curry TB, Convertino VA, Joyner MJ. Effect of systemic epinephrine infusion on tolerance to progressive central hypovolemia in humans, in preparation
- Johnson BD, van Helmond N, Holbein WW, Petersen-Jones H.G., Curry TB, Convertino VA, Joyner MJ. The role of the carotid bodies in mediating hemodynamic responses to lower body negative pressure during hypoxia, in preparation

Abstracts

- Johnson BD, van Helmond N, Curry TB, Convertino VA, & Joyner MJ. Hemodynamic responses during lower body negative pressure and hemorrhage in humans. *FASEB J* 27:1206.3, 2013.
- van Helmond N, Johnson BD, Curry TB, Convertino VA, & Joyner MJ. The association between pulse pressure and stroke volume during lower body negative pressure and graded hemorrhage. *FASEB J* 27:1206.4, 2013.
- Johnson BD, van Helmond N, Curry TB, Convertino VA, & Joyner MJ. Relationship of Central Venous Pressure to Hemodynamic Responses during Lower Body Negative Pressure and Hemorrhage. *Medicine and Science in Sports & Exercise* 45 (5S), S39, 2013.
- van Helmond N, Johnson BD, Effertz CM, Curry TB, & Joyner MJ. Heart rate variability during graded hemorrhage in humans. *Clinical Autonomic Research* 23: 284, 2013.
- Effertz CM, Johnson BD, van Helmond N, Convertino VA, Joyner MJ, & Curry TB. Cardiac baroreflex sensitivity during lower body negative pressure and graded hemorrhage in humans. *Clinical Autonomic Research* 23: 282, 2013.

- Johnson BD, van Helmond N, Curry TB, Convertino VA, & Joyner MJ. Catecholamine responses to central hypovolemia induced by lower body negative pressure and blood loss in humans. *FASEB J*, 28:707.2, 2014.
- Effertz CM, Johnson BD, Convertino VA, Joyner MJ, & Curry TB. Changes to erythrocyte markers during lower body negative pressure and graded blood loss in humans. *FASEB J*, 28:707.3, 2014.
- Barnes JN, Johnson BD, Convertino VA, Joyner MJ, & Rickards CA. Cerebral blood flow regulation during blood loss compared to lower body negative pressure in humans. *FASEB J*, 28:1068.9, 2014.
- Johnson BD, van Helmond N, Curry TB, Convertino VA, & Joyner MJ. The effects of blood re- infusion on hemodynamics following blood removal. *FASEB J*, 29:823.4, 2015.
- van Helmond N, Johnson BD, Curry TB, Cap AP, Convertino VA, & Joyner MJ. Blood coagulation during lower body negative pressure vs. blood loss in humans. *FASEB J*, 29:823.3, 2015.
- van Helmond N, Johnson BD, Curry TB, Cap AP, Convertino VA, Joyner MJ. White blood cell counts during lower body negative pressure vs. blood loss in humans. *FASEB J*, 30:1241.1, 2016.
- Petersen-Jones HG, Holbein WW, Johnson BD, Convertino VA, Curry TB, Joyner MJ. Activation of the chemo- and cardiopulmonary reflexes blunt baroreflex sensitivity through independent mechanisms. *FASEB J*, 30:1286.1, 2016.
- Holbein WW, Johnson BD, Convertino VA, Curry TB, Joyner MJ. Hemodynamic responses to simulated hemorrhage: Role for the carotid bodies. *FASEB J*, 30:1241.4, 2016.

- van Helmond N, Johnson BD, Holbein WW, Petersen-Jones H.G., Curry TB, Convertino VA, Joyner MJ. Effect of acute hypoxia on cerebral blood velocity during lower body negative pressure. Accepted for Experimental Biology 2017.
- Scruggs ZM, Petersen-Jones HG, Convertino VA, Joyner MJ, Curry TB, Baker SE. Epinephrine does not influence baroreflex sensitivity during lower body negative pressure to physiological tolerance. Accepted for Experimental Biology 2017.
- Aarts HM, Petersen-Jones HG, Johnson BD, Curry TB, Joyner MJ. Cardiac baroreflex sensitivity during lower body negative pressure and acute hypoxia: fainters vs. nonfainters. Accepted for Experimental Biology 2017.

Participants and Other Organizations

The following individuals have worked on the project:

Name: Michael Joyner, M.D.

Project Role: PI

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.90 calendar months

Contribution to Project: Oversee all aspects of the project.

Funding Support: N/A

Name: Timothy Curry, M.D., Ph.D.

Project Role: Co-I

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.22 calendar months

Contribution to Project: Oversee the invasive studies including line placement when Dr. Joyner was not available.

Funding Support: N/A

Name: Walter Holbein, Ph.D.

Project Role: Post-Doc

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 3.63 calendar months

Contribution to Project: Worked closely with Dr. Joyner on all aspects of the intellectual and operational conduct of the study. He also played a major role in primary data analysis and manuscript preparation.

Funding Support: N/A

Name: Shelly Roberts, R.N.

Project Role: Lead Nurse

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 1.16 calendar months

Contribution to Project: screening the subjects, care of research study participants, primary communication with subjects, coordination of recruitment, and routine compliance and communication with the IRB

Funding Support: N/A

Name: Sarah Wolhart, B.S.N.

Project Role: Nurse

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 2.22 calendar months

Contribution to Project: She worked closely with Shelly Roberts screening the subjects, care of research study participants, communicating with subjects, coordinating recruitment, and submitting IRB applications

Funding Support: N/A

Name: Jasmin McCabe, R.N.

Project Role: Nurse

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.89 calendar months

Contribution to Project: She worked closely with Shelly Roberts screening the subjects, care of research study participants, communicating with subjects, coordinating recruitment, and submitting IRB applications

Funding Support: N/A

Name: Chris Johnson

Project Role: Research Technician

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 1.90 calendar months

Contribution to Project: Data Analysis, aid in the conduct of the studies to include equipment set up, calibration, and data acquisition

Funding Support: N/A

Name: Andy Miller

Project Role: Sr. Research Technician

Research Identifier: N/A

Nearest Person month worked: From 9/14/2013-11/14/2016 1.21 calendar months

Contribution to Project: Data Analysis, aid in the conduct of the studies to include equipment set up, calibration, and data acquisition.

Funding Support: N/A

Name: Kate Russell (nee Malterer)

Project Role: Research Technician

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 1.84 calendar months

Contribution to Project: Data Analysis, study set up

Funding Support: N/A

Name: Maja Johnson

Project Role: Research Technician

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.63 calendar months

Contribution to Project: Data Analysis, study set up

Funding Support: N/A

Name: Mike Mozer

Project Role: Research Technician

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.71 calendar months

Contribution to Project: Data Analysis, study set up

Funding Support: N/A

Name: Gabie Dillion

Project Role: Research Assistant

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.21 calendar months

Contribution to Project: Data Analysis

Funding Support: N/A

Name: Lauren Newhouse

Project Role: Research Assistant

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.16 calendar months

Contribution to Project: Data Analysis

Funding Support: N/A

Name: Humphrey Peterson-Jones

Project Role: Research Assistant

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 1.09 calendar months

Contribution to Project: Data Analysis

Funding Support: N/A

Name: Zachariah Scruggs

Project Role: Research Assistant

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.28 calendar months

Contribution to Project: Data Analysis

Funding Support: N/A

Name: Pam Engrav

Project Role: Scheduler

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 1.62 calendar months

Contribution to Project: Recruit study subjects

Funding Support: N/A

Name: Nancy Meyer

Project Role: Scheduler

Research Identifier: N/A

Nearest Person month worked : From 9/14/2013-11/14/2016 0.34 calendar months

Contribution to Project: Recruit study subjects when Pam Engrav was not available.

Funding Support: N/A

From 9/14/2013-11/14/2016, the following individuals worked less than 1 person month on the project: John Eisenach (Co-I), Dr. John Eisenach left Mayo in June 2014 and has not been working on this project since that time Noud van Helmond (Post-Doc), , Blair Johnson (Post-Doc), Sarah Baker (Post-Doc), Branton Walker (Technician)

There were no other organizations involved as partners.

Appendices

Please see the attached original manuscripts of 4 published journal articles.

White Blood Cell Concentrations during Lower Body Negative Pressure and Blood Loss in Humans

Noud van Helmond¹, Blair D. Johnson^{1,2}, Timothy B. Curry¹, Andrew P. Cap³, Victor A. Convertino³, & Michael J. Joyner¹

¹Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota

²Center for Research and Education in Special Environments, Department of Exercise and Nutrition Sciences, University at Buffalo, Buffalo, New York

³U.S. Army Institute of Surgical Research, Fort Sam Houston, TX

Disclaimer:

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Department of the Army or the US Department of Defense.

Conflicts of Interest and Source of Funding: No conflicts of interest. Support for this study was provided by U.S. Army MPMC Combat Casualty Care Research Program Grant W81XWH-11-1-0823 to MJJ, American Heart Association Midwest Affiliate Grant 13POST-14380027 to B.D.J., and by Dutch Heart Foundation E. Dekker Stipend 2012SB013 to N.V.H.

Running Head: WBC concentrations during LBNP and blood loss

Corresponding Author:

Blair D. Johnson, PhD

208A Kimball Tower

Buffalo, New York 14214

Email: blairjoh@buffalo.edu

Phone: 716-829-6789

Fax: 716-829-2428

1. What is the central question of this study?

Is lower body negative pressure a useful surrogate to study white blood cell responses to hemorrhage in humans?

2. What is the main finding and its importance?

We found that lower body negative pressure appears to be a useful surrogate to study the early white blood cell mobilization response during blood loss.

ABSTRACT

Hypovolemia has been associated with an immune response that might be secondary to sympathoexcitation. We tested the hypothesis that simulated hypovolemia using lower body negative pressure (LBNP) and actual hypovolemia induced via experimental blood loss (BL) cause similar increases in white blood cell concentrations ([WBC]). We measured [WBC] and catecholamine concentrations in twelve men who performed a LBNP and BL protocol in a randomized order. We compared 45 mmHg of LBNP to 1000 mL of BL; therefore [WBC] and catecholamine concentrations were plotted against central venous pressure (CVP) to obtain stimulus-response relationships using the linear regression line slopes for both protocols. Mean regression line slopes were similar for total [WBC] (LBNP 183 ± 46 vs. BL 155 ± 109 $\text{mL}^{-1} \times \text{mmHg}^{-1}$, $p=0.15$), neutrophils (LBNP 110 ± 29 vs. BL 96 ± 72 $\text{mL}^{-1} \times \text{mmHg}^{-1}$, $p=0.15$) and lymphocytes (LBNP 65 ± 21 vs. BL 59 ± 38 $\text{mL}^{-1} \times \text{mmHg}^{-1}$, $p=0.90$). Mean regression line slopes for adrenaline were similar (LBNP 15 ± 5 vs. BL 16 ± 4 $\text{pg} \times \text{mL}^{-1} \times \text{mmHg}^{-1}$, $p=0.84$), and were steeper during LBNP for noradrenaline (LBNP 28 ± 6 vs. BL 9 ± 6 $\text{pg} \times \text{mL}^{-1} \times \text{mmHg}^{-1}$, $p=0.01$). These data indicate that central hypovolemia elicits a relative leukocytosis with a predominantly neutrophil-based response. Additionally, our results indicate that LBNP models the stimulus-response relationship between CVP and [WBC] observed during BL.

Key words: Leukocytosis; Hemorrhage; Humans; Central Hypovolemia

INTRODUCTION

Hemorrhage is one of the leading causes of accidental death (Boulanger *et al.*, 2007) and is the leading cause of preventable death on the battlefield (Eastridge *et al.*, 2011; Eastridge *et al.*, 2012). Trauma and hemorrhagic shock are associated with an acute increase in circulating leukocytes (Thommasen *et al.*, 1986; Teggatz *et al.*, 1987; Yanagawa *et al.*, 2005), which might prevent infection and promote wound healing following tissue damage. Therefore, examining the leukocytosis response to blood loss (BL) is important to gain insight into mechanisms that may prevent or render hemorrhage victims prone to infection and impaired wound healing. Animal studies have evaluated the mechanisms of hemorrhagic leukocytosis (Musser, 1921; Gaylor *et al.*, 1969); however, using invasive methods to experimentally induce BL and evaluate hemorrhage-induced leukocytosis is challenging to perform in humans.

Barcroft and colleagues were pioneers in studying the physiological responses to BL in human subjects. They sequestered blood in the legs using venous tourniquets placed around the thighs in combination with venesection. This technique allowed Barcroft and colleagues to induce fainting and quickly increase venous return by releasing the venous tourniquets to restore consciousness (Barcroft *et al.*, 1944). Similar to this method, lower body negative pressure (LBNP) has emerged as a non-invasive surrogate to study many of the physiological responses to BL (Cooke *et al.*, 2004; Hinojosa-Laborde *et al.*, 2014; Johnson *et al.*, 2014). LBNP sequesters circulating blood in the lower body thereby reducing central blood volume and mimicking hemodynamic and blood coagulation responses generated during BL (Cooke *et al.*, 2004; Hinojosa-Laborde *et al.*, 2014; Johnson *et al.*, 2014; Rickards *et al.*, 2015). However, we are unaware of any data that supports the notion that LBNP influences circulating leukocytes to the same extent as BL. It has been suggested that catecholamines cause the leukocytosis associated with hypovolemic shock (Yanagawa *et al.*, 2005). Since reductions in central blood volume by experimental BL or LBNP increase catecholamine concentrations to a similar extent (Cooke *et al.*, 2004; Hinojosa-Laborde *et al.*, 2014; Johnson *et al.*, 2014), it seems reasonable to expect that LBNP

might elicit comparable changes in circulating leukocytes when the degree of central hypovolemia is similar between LBNP and BL.

To explore whether LBNP can be used as a model to study the leukocytosis associated with BL, we compared concentrations of circulating leukocytes during LBNP to those generated during BL in humans. We hypothesized that the stimulus-response relationships of central hypovolemia (i.e. central venous pressure) and catecholamine concentrations to circulating leukocytes during LBNP would be similar to those observed during BL for a given central hypovolemic stimulus.

MATERIALS AND METHODS

Ethical Approval

This study was approved by the Mayo Clinic Institutional Review Board and conformed to the standards set by the 2008 revision of the Declaration of Helsinki (Williams, 2008). Prior to participation, all subjects provided written informed consent after all procedures and study risks were fully explained.

Subjects

Twelve healthy men (age: 32 ± 6 years; height: 181.8 ± 6.8 cm; weight: 88.4 ± 8.8 kg; BMI: 26.7 ± 1.8 kg $\times$ m⁻²) participated in this study. Subjects were non-smokers, and did not take any medications. All subjects reported to be free of cardiovascular, respiratory, neurologic, and metabolic disease. Following an overnight fast, subjects reported to the Clinical Research Trial Unit (CRTU) of the Mayo Clinic at 0700. Upon reporting to the CRTU, subjects consumed a snack (Cliff Bar; Shelton, CT, USA; 240 kcals) and drank 250 mL of water. Subjects were studied in the supine position in a temperature-controlled room (20-22° C).

Experimental Design

The study timeline is presented in Figure 1. The experimental design and selection of LBNP and BL protocols have been detailed in previously publications that focused on testing the hypotheses that hemodynamic (Johnson *et al.*, 2014), coagulation (Helmond *et al.*, 2015), and cerebral blood velocity (Rickards *et al.*, 2015) responses would be similar between LBNP and BL. In the present paper, we uniquely test the hypothesis that the WBC response associated with hemorrhage will be similar during progressive reduction in central blood volume induced by LBNP.

Both protocols were performed on the same day and the order was randomized and counterbalanced. Briefly, subjects were studied supine and instrumented for blood removal (brachial vein catheter) and monitoring (brachial artery catheter and peripherally inserted central catheter (PICC)). After the first protocol, subjects rested quietly for 45-75 minutes in the supine position. The protocols were terminated

if mean arterial pressure fell by 30%, systolic blood pressure dropped below 80 mmHg, or the subject began to experience symptoms of pre-syncope or syncope. Arterial blood samples were collected at baseline and at the conclusion of each protocol. During the LBNP protocol, blood samples were collected shortly before suction was terminated. If a protocol was terminated early, blood samples were obtained immediately upon the decision to terminate the protocol.

LBNP protocol

Subjects laid in an LBNP chamber sealed at the iliac crest. The LBNP protocol was based on the first 3 stages of the protocol frequently used by the U.S. Army Institute of Surgical Research (Cooke *et al.*, 2004) (Figure 1). Following a 5-minute baseline period, the protocol commenced and consisted of 5-minute stages at 15, 30, and 45 mmHg of LBNP. Subjects were instructed not to move during the protocol.

Blood Loss protocol

Preservative/anticoagulant bags (63 mL anti-coagulant citrate phosphate dextrose solution) were positioned below the subject to enable blood transfer from the subject via gravity from a large bore intravenous catheter. Following a 5-minute baseline period, 3 aliquots of 333 mL of blood were removed. After each aliquot of blood was removed, the subject rested for a 5-minute period to emulate the timing of the LBNP protocol. The removed blood was kept in the study room (20-22°C) and was re-infused at a rate of $20 \text{ mL} \times \text{min}^{-1}$ into the antecubital vein following the BL protocol.

Hemodynamic measurements

Heart rate (HR) was measured from a 3-lead ECG (Cardiacap/5, Datex-Ohmeda, Louisville, CO, USA). Blood pressure was measured beat-by-beat by arterial catheter. Central venous pressure (CVP) was measured using the PICC. The PICC was introduced through an antecubital vein and advanced to the level of the superior vena cava. Placement of the PICC was estimated using external measurement of the distance from the antecubital fossa to the manubrium and was verified by the identification of a typical CVP waveform. All lines were placed aseptically with local anesthesia. The arterial catheter and the

PICC were connected to pressure transducers (FloTrac, Edwards Lifesciences Corp., Irvine, CA, USA) placed at the mid-axillary line.

Complete blood counts and Catecholamines

Blood was collected from the brachial artery catheter for the measurement of complete blood cell and circulating catecholamine concentrations. The Department of Laboratory Medicine and Pathology and the Immunochemistry Core Laboratory of the CRTU of the Mayo Clinic Center for Clinical and Translational Science analyzed the blood samples for complete blood cell concentrations and circulating catecholamines, respectively. Blood samples collected in 3 mL EDTA tubes were analyzed for red blood cell concentrations [RBC], white blood cell concentrations [WBC] and WBC differential using an automated analyzer according to the RF/DC detection method (Sysmex XE-5000, Kobe, Japan). Plasma adrenaline and noradrenaline concentrations were determined from 4.5 mL of arterial blood using HPLC after prior alumina extraction (ESA Coulochem III, Dionex, Sunnyvale, CA, USA).

Hemoconcentration measures

Baseline total blood volume was estimated according to Retzlaff et al. (Retzlaff *et al.*, 1969) using the following equation:

$$\text{Blood volume} = 31.9 \times \text{height (cm)} + 26.3 \times \text{weight (kg)} - 2402$$

Estimated changes in blood volume and the estimated percentage change in plasma volume from pre to post LBNP and from pre to post BL were determined using the formula by Dill and Costill (Dill & Costill, 1974). Hemoglobin values were corrected for volume of blood withdrawn and baseline plasma percentage was defined as 1-hematocrit.

Data and statistical analysis

Hemodynamic data were collected and analyzed off-line using signal processing software (WinDaq, DATAQ Instruments, Akron, OH, USA). Hemodynamic data were analyzed and averaged over the last 2 minutes of baseline and final stages of LBNP and BL for statistical analysis. All hemodynamic signals were automatically peak-detected and manually verified. Stroke volume (SV) was determined using WinCPRS software (Absolute Aliens Oy, Turku, Finland) by selecting the area under the arterial blood pressure curve and calculated using Modelflow (Wesseling *et al.*, 1993). Cardiac output was calculated as the product of heart rate and stroke volume. Protocol (LBNP/BL) $\times$ time (Baseline/Protocol termination) repeated measures ANOVA was used to determine if values obtained during the LBNP protocol were similar to values during the BL protocol. If a significant main or interaction effect was obtained, Tukey's post hoc test was performed to determine where differences existed. If data were not normally distributed, the Wilcoxon Signed Rank test was used. As a post hoc test, we compared the relationship of white blood cell counts and catecholamines vs. hypovolemia during BL and LBNP to adjust for differences in hypovolemia. We performed this analysis by plotting white blood cell concentrations and catecholamine concentrations against CVP to obtain stimulus-response relationships using the linear regression line slopes as we (Johnson *et al.*, 2014; Helmond *et al.*, 2015) and others (Rea *et al.*, 1991) have done. CVP decreases early and linearly throughout both LBNP and BL protocols (Gauer *et al.*, 1956; Henry *et al.*, 1956; Norsk *et al.*, 1986; Hirsch *et al.*, 1989; Rea *et al.*, 1991; van Hoeyweghen *et al.*, 2001; Hinojosa-Laborde *et al.*, 2014; Johnson *et al.*, 2014). To assess the relationship of the white blood cell concentrations vs. catecholamines during BL and LBNP, we performed a similar analysis by plotting the white blood cell concentrations that increased against catecholamine concentrations. Paired t-tests were used to determine if the slopes of these regression lines were different between protocols. Group data are presented as mean $\pm$ SE and P values are reported.

RESULTS

Of the twelve subjects, two did not complete both protocols (both subjects completed 667 mL of BL and 30 mmHg of LBNP); additionally, one subject did not complete the LBNP protocol (completed 30 mmHg of LBNP), and one subject did not complete the BL protocol (completed 333 mL of BL). These protocols were terminated early due to pre-syncope symptoms or syncope. Data obtained from the final completed stage were used for these subjects. The mean hemodynamic values obtained during both protocols are presented in Table 1 and are reported elsewhere (Johnson *et al.*, 2014). Complete [WBC], catecholamine concentrations, and [RBC] at baseline and protocol termination are shown in Table 1. The mean [WBC] and catecholamine concentrations across the range of CVP during LBNP and BL are displayed in Figures 2 and 3. Regression line slopes produced from the stimulus-response relationships between the mean [WBC] and catecholamine concentrations are illustrated in Figure 4.

Effects of LBNP and BL on Hemodynamics

Table 1 shows that both LBNP and BL evoked pronounced hemodynamic changes from baseline to protocol termination. At baseline, CVP ($p=0.024$) was slightly lower during BL while SV ($p=0.016$), and CO ($p=0.045$) were slightly higher. Overall, 45 mmHg of LBNP caused greater changes in hemodynamic parameters than 1000 mL of BL. Specifically, at protocol termination, CVP ($p<0.001$), SV ($p<0.001$) and CO ($p=0.002$) were lower and HR was higher ($p<0.001$) during LBNP versus BL.

Effects of LBNP and BL on White Blood Cell Concentrations

Total [WBC] was increased at LBNP termination ($p<0.001$) and at BL termination ($p=0.100$) (Table 1). Total [WBC] was higher during LBNP versus BL at protocol termination ($p=0.040$). Neutrophil concentration was increased at LBNP termination ($p=0.001$) and at BL termination ($p=0.080$). Lymphocyte concentration was also increased at protocol termination in LBNP ($p=0.005$). Monocyte, eosinophil, and basophil concentrations remained relatively unchanged at both LBNP and BL

termination. Importantly, the regression line slopes calculated from the relationship between the various [WBC] and CVP were not different between LBNP and BL.

Effects of LBNP and BL on Catecholamine Concentrations

Adrenaline ($p<0.001$ and $p=0.002$) and noradrenaline ($p<0.001$ and $p=0.043$) concentrations were both elevated at LBNP and BL protocol termination, respectively (Table 1). Noradrenaline concentrations were higher during LBNP versus BL at protocol termination ($p=0.003$). Regression line slopes produced from the stimulus-response relationship between adrenaline and CVP were not different during LBNP and BL. The noradrenaline response slopes were steeper during LBNP vs. BL (28 ± 19 vs. 9 ± 20 $\text{pg} \times \text{mL}^{-1} \times \text{mmHg}^{-1}$, $p=0.010$) (Figure 3).

Relationship of White Blood Cell Concentrations vs. Catecholamines

Regression line slopes produced from the stimulus-response relationships between the total [WBC], neutrophils, lymphocytes and adrenaline were not different during LBNP and BL (Figure 4). Regression line slopes from the relationships between total [WBC], neutrophils, lymphocytes and noradrenaline were also not different during LBNP and BL.

Effects of LBNP and BL on Hemoconcentration

Several markers indicated that LBNP caused hemoconcentration, while BL induced hemodilution (Table 1). After LBNP, there were increases in hemoglobin ($p=0.003$) and hematocrit ($p=0.001$) and a decrease in estimated plasma volume ($p=0.001$) compared to baseline values. BL induced decreases in hemoglobin ($p=0.006$) and hematocrit ($p=0.006$) and an increase in estimated plasma volume ($p=0.004$) compared to baseline values. At protocol termination, hemoglobin ($p=0.001$) and hematocrit ($p=0.001$) were lower in BL versus LBNP and estimated plasma volume ($p\leq0.001$) was greater in BL when compared to LBNP.

DISCUSSION

The results of this study indicate that BL and LBNP induce similar leukocyte response slopes across a wide range of CVP. A reduction in CVP resulting from central hypovolemia by LBNP induced a relative leukocytosis with a predominantly neutrophil-based response and a slight increase in lymphocytes. Additionally, neutrophil and lymphocyte concentrations were relatively unchanged during BL. This indicates that a greater hypovolemic stimulus, such as that which occurred during LBNP, is needed to increase neutrophil and lymphocyte numbers.

To our knowledge, this is the first experimental study reporting the early WBC mobilization in response to central hypovolemia induced by BL or LBNP. The increase in total leukocytes we found during LBNP is consistent with previous reports that found an increase in total leukocytes during a combination of LBNP and whole body heating (Meyer *et al.*, 2013). The increase in neutrophils and lymphocytes we found during LBNP are consistent with the immune cell responses observed during hypovolemic shock in clinical settings (Thommasen *et al.*, 1986; Tegatz *et al.*, 1987; Yanagawa *et al.*, 2005) and experimental hemorrhage in animals (Musser, 1921; Gaylor *et al.*, 1969). The increase in circulating leukocytes is related to the sympathetic responses to trauma (Thommasen *et al.*, 1986; Tegatz *et al.*, 1987; Yanagawa *et al.*, 2005) and may contribute to wound healing under these conditions (Benschop *et al.*, 1996; Dhabhar *et al.*, 2012). Our findings demonstrate that increases in WBC can be stimulated by a reduction in central blood volume without tissue injury. Previous investigations have described a pronounced leukocytosis with lymphocytosis and neutrophilia after subcutaneous injection of adrenaline in both animals (Frey, 1914) and humans (Loeper & Crouzon, 1904). Additionally, experimentally induced psychological stress (Dhabhar *et al.*, 2012) and physical exercise (Pedersen & Hoffman-Goetz, 2000), both of which increase circulating catecholamines, lead to increases in lymphocyte and neutrophil concentrations. Therefore, it is probable that the elevated circulating catecholamines observed in both LBNP and BL protocols account for the rise in circulating neutrophils and lymphocytes.

The increase in circulating lymphocytes following an increase in adrenaline is mediated via activation of

β_2 -adrenoceptors, whereas α -adrenoceptor stimulation contributes to the increase in circulating neutrophils (Benschop *et al.*, 1996; Sanders, 2006). We found significant increases in adrenaline after both LBNP and BL and the regression line slopes calculated from the relationship between the total [WBC], neutrophils, lymphocytes and adrenaline values were not different between protocols. Therefore, sympathoexcitation and the release of adrenaline likely contributed to the relative leukocytosis. Noradrenaline was also significantly elevated after both LBNP and BL, but noradrenaline has limited influence on leukocyte numbers (Benschop *et al.*, 1996).

In addition to the greater hypovolemic stimulus that LBNP produced, we observed divergent effects on plasma volume during LBNP and BL. We found a decrease in plasma volume by ~4% during LBNP, and plasma volume increased by ~3% during BL. This is a direct result of how these protocols cause central hypovolemia. The suction applied during LBNP produces a pressure gradient that pulls fluid from the intravascular compartment to the extravascular space in the lower body resulting in hemoconcentration (Sander-Jensen *et al.*, 1988; Ward *et al.*, 2010; Cvirn *et al.*, 2012). However, BL has the opposite effect. The reduction in circulating blood volume causes fluid to shift from the extravascular space to the intravascular space resulting in hemodilution (Riddez *et al.*, 1998; Drobin & Hahn, 1999; Zaar *et al.*, 2014). This divergent effect on plasma volume likely contributed to the greater increase in white blood cells during LBNP.

We observed a relative leukocytosis at the immediate termination of both LBNP and BL. The immune cell response to stress, exercise, and to adrenaline injection all show a biphasic pattern, with an initial lymphocytosis and a maximal response within 30 minutes of the stimulus. This increase is followed by a maximal rise in neutrophils that occurs between two and four hours following the stimulus (Samuels, 1951; Pedersen & Hoffman-Goetz, 2000; Dhabhar *et al.*, 2012). Therefore, we might have observed a greater increase in neutrophil concentrations if we would have prolonged the hypovolemic exposures or postponed blood sample collection until 2-4 hours following each protocol. However, we did not find an order effect such that the observed responses were not dependent on whether LBNP or BL occurred

first. Therefore, a delay in blood sample collection would not have resulted in a marked increase in neutrophils following our protocols.

Methodological considerations

Several methodological considerations pertain and additional limitations have been considered elsewhere (Johnson *et al.*, 2014; Helmond *et al.*, 2015). First, we collected blood only at baseline and at the termination of each protocol. Collecting multiple samples throughout both protocols might have allowed us to identify whether a biphasic leukocyte response exists during central hypovolemia elicited by LBNP or BL. Second, the maximal hypovolemic stimulus during LBNP, as measured by the change in cardiovascular parameters likely was greater when compared to BL. Additionally, it is likely that the differing profiles of central blood volume reduction during BL (i.e., slower rate) vs. LBNP in the present study influenced the hemodynamic responses and leukocyte changes. Progressive LBNP was applied continuously without any break in the stimulus. In contrast, the BL protocol had intermittent reductions in central blood volume. The smaller changes in hemodynamic variables and leukocytes during the BL protocol might reflect the ability of compensatory responses to react to a slower rate of central blood volume reduction. Third, we have no direct recordings of sympathetic neural activity, which could have provided additional insight regarding interpretation of the magnitude of sympathetic nervous system activation during central hypovolemia. Fourth, catecholamine induced immune cell redistribution accompanies increases in immune function (Dhabhar *et al.*, 2012). Therefore, it would have been informative if we had performed specific immune function tests in addition to determining cell concentrations.

CONCLUSIONS

Reductions in CVP elicit early relative leukocytosis with a predominantly neutrophil-based response. The stimulus-response slopes for leukocyte concentrations versus CVP were similar between the two protocols, which indicates that LBNP elicits a relative leukocytosis similar to BL within the range of central hypovolemia that we tested. Additionally, the increase in WBC during LBNP and/or BL can be

achieved in the absence of tissue injury. Therefore, LBNP appears to be a useful surrogate to study the early WBC mobilization response during BL.

AUTHOR CONTRIBUTIONS

Author contributions: N.v.H., B.D.J., T.B.C., and M.J.J. performed experiments; N.v.H. and B.D.J. analyzed data; N.v.H., B.D.J., T.B.C., A.P.C., V.A.C., and M.J.J. interpreted results of experiments; N.v.H. prepared figures; N.v.H. drafted manuscript; N.v.H., B.D.J., T.B.C., A.P.C., V.A.C., and M.J.J. edited and revised manuscript; N.v.H., B.D.J., T.B.C., A.P.C., V.A.C., and M.J.J. approved final version of manuscript; B.D.J., T.B.C., A.P.C., V.A.C., and M.J.J. conception and design of research.

ACKNOWLEDGEMENTS

We thank the subjects who participated in the study. We also thank Shelly K. Roberts, Sara C. Wolhart, Christopher P. Johnson, Margaret McGill-Zimny, and David Warren for their assistance.

FUNDING

Support for this study was provided by U.S. Army MRMC Combat Casualty Care Research Program Grant W81XWH-11-1-0823 to MJJ, American Heart Association Midwest Affiliate Grant 13POST-14380027 to B.D.J., and by Dutch Heart Foundation E. Dekker Stipend 2012SB013 to N.V.H.

ABBREVIATIONS

LBNP: Lower body negative pressure; BL: blood loss; CVP: central venous pressure; PICC; peripherally inserted central catheter; WBC: white blood cell; RBC: red blood cell; HR: heart rate; MAP: mean arterial pressure; SV: stroke volume; CO: cardiac output; CRTU: Clinical Research Trial Unit; BMI: body mass index

Table 1. Effects of LBNP and BL on hemodynamic variables, white blood cell concentrations, catecholamine concentrations, red blood cell concentration and plasma volume.

		Baseline	Termination
<i>Hemodynamic variables</i>			
CVP (mmHg)	LBNP	7.3 ± 2.2	-0.2 ± 2.0 [*]
	BL	6.1 ± 2.1 [†]	1.8 ± 2.7 ^{*†}
HR (bpm)	LBNP	60 ± 8.7	80 ± 17.5 [*]
	BL	60 ± 9.7	67 ± 9.1 ^{*†}
MAP (mmHg)	LBNP	93.5 ± 8.1	84.5 ± 10.1 [*]
	BL	91.8 ± 6.7	87.0 ± 9.5
SV (mL)	LBNP	83.2 ± 9.4	54.1 ± 11.4 [*]
	BL	89.5 ± 9.4 [†]	70.5 ± 9.4 ^{*†}
CO (L × min ⁻¹)	LBNP	5.0 ± 1.0	4.1 ± 0.3 [*]
	BL	5.3 ± 1.0 [†]	4.7 ± 0.7 ^{*†}
<i>White blood cell concentrations</i>			
Total leukocytes (×10 ⁹ × L ⁻¹)	LBNP	5.6 ± 1.1	6.8 ± 1.8 [*]
	BL	5.2 ± 1.5	5.6 ± 2.1 [†]
Neutrophils (×10 ⁹ × L ⁻¹)	LBNP	3.6 ± 1.2	4.3 ± 1.4 [*]
	BL	3.1 ± 1.4	3.4 ± 1.9
Lymphocytes (×10 ⁹ × L ⁻¹)	LBNP	1.4 ± 0.4	1.9 ± 0.7 [*]
	BL	1.5 ± 0.4	1.6 ± 0.5
Monocytes (×10 ⁹ × L ⁻¹)	LBNP	0.41 ± 0.10	0.47 ± 0.15
	BL	0.44 ± 0.10	0.41 ± 0.07
Eosinophils (×10 ⁹ × L ⁻¹)	LBNP	0.13 ± 0.06	0.13 ± 0.06
	BL	0.15 ± 0.09	0.13 ± 0.08
Basophils (×10 ⁹ × L ⁻¹)	LBNP	0.02 ± 0.01	0.03 ± 0.02
	BL	0.02 ± 0.01	0.03 ± 0.01

Catecholamine concentrations

Noradrenaline (pg $\times$ mL ⁻¹)	LBNP	148 $\pm$ 70	354 $\pm$ 153 [*]
	BL	155 $\pm$ 75	211 $\pm$ 102 ^{*†}
Adrenaline (pg $\times$ mL ⁻¹)	LBNP	53 $\pm$ 26	144 $\pm$ 105 [*]
	BL	49 $\pm$ 20	103 $\pm$ 61 [*]

Red blood cell concentration and plasma volume

Hemoglobin (g/dL)	LBNP	14.2 $\pm$ 1.4	14.7 $\pm$ 1.2 [*]
	BL	14.3 $\pm$ 1.3	14.0 $\pm$ 1.3 ^{*†}
Hematocrit (%)	LBNP	41 $\pm$ 2.8	42 $\pm$ 2.9 [*]
	BL	41 $\pm$ 2.9	40 $\pm$ 3.0 ^{*†}
RBC ($\times 10^{12} \times$ L ⁻¹)	LBNP	4.8 $\pm$ 0.4	5.0 $\pm$ 0.3 [*]
	BL	4.8 $\pm$ 0.4	4.7 $\pm$ 0.4 ^{*†}
Plasma volume (%)	LBNP	59 $\pm$ 2.8	56 $\pm$ 3.3 [*]
	BL	59 $\pm$ 2.9	61 $\pm$ 3.9 ^{*†}

LBNP = lower body negative pressure; BL = blood loss; CVP = central venous pressure; HR = heart rate; MAP = mean arterial pressure; SV = stroke volume; CO = cardiac output.

Values are means $\pm$ standard deviation, n = 12.

^{*}Different from Baseline (P < 0.05); [†]Different vs. LBNP

Figure 1. Timeline of the lower body negative pressure and blood loss protocols. The order of the protocols was randomized. When the lower body negative pressure protocol was performed first, 45 minutes of quiet rest was given between protocols to ensure hemodynamic variables returned to baseline. To allow for the reinfusion of removed blood, 75 minutes of quiet resting was given to allow for hemodynamic variables to return to baseline between protocols when blood loss occurred first. Blood was drawn at baseline and during the last stage of each protocol.

Figure 2. Mean $\pm$ SD white blood cell concentrations: (A) total white blood cell concentration, (B) neutrophil concentration, (C) lymphocyte concentration, (D) monocyte concentration, (E) eosinophil concentration, and (F) basophil concentration plotted against mean central venous pressure (CVP) $\pm$ SD at baseline and immediately after protocol termination during the LBNP and BL protocols. None of the response slopes were different between LBNP and BL protocols.

Figure 3. Mean $\pm$ SD (A) adrenaline and (B) noradrenaline concentrations plotted against mean CVP $\pm$ SD at baseline and immediately after protocol termination during the LBNP and BL protocols. Adrenaline response slopes were not different between LBNP and BL protocols and noradrenaline response slopes were steeper during LBNP ($p=0.01$).

Figure 4. Mean $\pm$ SD white blood cell concentrations plotted against mean $\pm$ SD catecholamine concentrations at baseline and immediately after protocol termination during the LBNP and BL protocols. (A) Total white blood cell concentration, (B) neutrophil concentration and (C) lymphocyte concentration plotted against adrenaline concentrations. (D) Total white blood cell concentration, (E) neutrophil concentration and (F) lymphocyte concentration plotted against noradrenaline concentrations. None of the response slopes were different between LBNP and BL protocols.

REFERENCES

- Barcroft H, Edholm O, McMichael J & Sharpey-Schafer E (1944). Posthaemorrhagic fainting study by cardiac output and forearm flow. *Lancet*, 489-491.
- Benschop RJ, Rodriguez-Feuerhahn M & Schedlowski M (1996). Catecholamine-induced leukocytosis: early observations, current research, and future directions. *Brain Behav Immun* **10**, 77-91.
- Boulanger L, Joshi AV, Tortella BJ, Menzin J, Caloyeras JP & Russell MW (2007). Excess mortality, length of stay, and costs associated with serious hemorrhage among trauma patients: findings from the National Trauma Data Bank. *Am Surg* **73**, 1269-1274.
- Cooke WH, Ryan KL & Convertino VA (2004). Lower body negative pressure as a model to study progression to acute hemorrhagic shock in humans. *J Appl Physiol (1985)* **96**, 1249-1261.
- Cvirn G, Schlagenhaut A, Leschnik B, Koestenberger M, Roessler A, Jantscher A, Vrecko K, Juergens G, Hinghofer-Szalkay H & Goswami N (2012). Coagulation changes during presyncope and recovery. *PLoS One* **7**, e42221.
- Dhabhar FS, Malarkey WB, Neri E & McEwen BS (2012). Stress-induced redistribution of immune cells--from barracks to boulevards to battlefields: a tale of three hormones--Curt Richter Award winner. *Psychoneuroendocrinology* **37**, 1345-1368.
- Dill DB & Costill DL (1974). Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. *J Appl Physiol* **37**, 247-248.
- Drobin D & Hahn RG (1999). Volume kinetics of Ringer's solution in hypovolemic volunteers. *Anesthesiology* **90**, 81-91.
- Eastridge BJ, Hardin M, Cantrell J, Oetjen-Gerdes L, Zubko T, Mallak C, Wade CE, Simmons J, Mace J, Mabry R, Bolenbaucher R & Blackbourne LH (2011). Died of wounds on the battlefield: causation and implications for improving combat casualty care. *J Trauma* **71**, S4-8.
- Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, Mallett O, Zubko T, Oetjen-Gerdes L, Rasmussen TE, Butler FK, Kotwal RS, Holcomb JB, Wade C, Champion H, Lawnick M, Moores L & Blackbourne LH (2012). Death on the battlefield (2001-2011): implications for the future of combat casualty care. *J Trauma Acute Care Surg* **73**, S431-437.
- Frey W (1914). Der Einfluss des vegetativen Nervensystems auf das Blutbild. *Z. Gesamte Exp. Med.* **2**, 38-49.

- Gauer OH, Henry JP & Sieker HO (1956). Changes in central venous pressure after moderate hemorrhage and transfusion in man. *Circ Res* **4**, 79-84.
- Gaylor MS, Chervenick PA & Boggs DR (1969). Neutrophil kinetics after acute hemorrhage. *Proc Soc Exp Biol Med* **131**, 1332-1336.
- Helmond N, Johnson BD, Curry TB, Cap AP, Convertino VA & Joyner MJ (2015). Coagulation changes during lower body negative pressure and blood loss in humans. *Am J Physiol Heart Circ Physiol* **309**, H1591-1597.
- Henry JP, Gauer OH & Sieker HO (1956). The effect of moderate changes in blood volume on left and right atrial pressures. *Circ Res* **4**, 91-94.
- Hinojosa-Laborde C, Shade RE, Muniz GW, Bauer C, Goei KA, Pidcock HF, Chung KK, Cap AP & Convertino VA (2014). Validation of lower body negative pressure as an experimental model of hemorrhage. *J Appl Physiol (1985)* **116**, 406-415.
- Hirsch AT, Levenson DJ, Cutler SS, Dzau VJ & Creager MA (1989). Regional vascular responses to prolonged lower body negative pressure in normal subjects. *Am J Physiol* **257**, H219-225.
- Johnson BD, van Helmond N, Curry TB, van Buskirk CM, Convertino VA & Joyner MJ (2014). Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses. *J Appl Physiol (1985)* **117**, 131-141.
- Loeper M & Crouzon O (1904). l'Action de l'adrenaline sur le sang. *Arch. Med. Exp. Anat. Pathol.* **16**, 83-108.
- Meyer MA, Ostrowski SR, Overgaard A, Ganio MS, Secher NH, Crandall CG & Johansson PI (2013). Hypercoagulability in response to elevated body temperature and central hypovolemia. *J Surg Res* **185**, e93-100.
- Musser J (1921). The leukocytes after hemorrhages. *Am J Med Sci* **162**, 40-46.
- Norsk P, Bonde-Petersen F & Warberg J (1986). Influence of central venous pressure change on plasma vasopressin in humans. *J Appl Physiol (1985)* **61**, 1352-1357.
- Pedersen BK & Hoffman-Goetz L (2000). Exercise and the immune system: regulation, integration, and adaptation. *Physiol Rev* **80**, 1055-1081.
- Rea RF, Hamdan M, Clary MP, Randels MJ, Dayton PJ & Strauss RG (1991). Comparison of muscle sympathetic responses to hemorrhage and lower body negative pressure in humans. *J Appl Physiol (1985)* **70**, 1401-1405.

Retzlaff JA, Tauxe WN, Kiely JM & Stroebel CF (1969). Erythrocyte volume, plasma volume, and lean body mass in adult men and women. *Blood* **33**, 649-661.

Rickards CA, Johnson BD, Harvey RE, Convertino VA, Joyner MJ & Barnes JN (2015). Cerebral blood velocity regulation during progressive blood loss compared with lower body negative pressure in humans. *J Appl Physiol* (1985) **119**, 677-685.

Riddez L, Johnson L & Hahn RG (1998). Central and regional hemodynamics during crystalloid fluid therapy after uncontrolled intra-abdominal bleeding. *J Trauma* **44**, 433-439.

Samuels AJ (1951). Primary and secondary leucocyte changes following the intramuscular injection of epinephrine hydrochloride. *J Clin Invest* **30**, 941-947.

Sander-Jensen K, Mehlsen J, Stadeager C, Christensen NJ, Fahrenkrug J, Schwartz TW, Warberg J & Bie P (1988). Increase in vagal activity during hypotensive lower-body negative pressure in humans. *Am J Physiol* **255**, R149-156.

Sanders VM (2006). Interdisciplinary research: noradrenergic regulation of adaptive immunity. *Brain Behav Immun* **20**, 1-8.

Teggatz JR, Parkin J & Peterson L (1987). Transient atypical lymphocytosis in patients with emergency medical conditions. *Arch Pathol Lab Med* **111**, 712-714.

Thommasen HV, Boyko WJ, Montaner JS, Russell JA, Johnson DR & Hogg JC (1986). Absolute lymphocytosis associated with nonsurgical trauma. *Am J Clin Pathol* **86**, 480-483.

van Hoeyweghen R, Hanson J, Stewart MJ, Dethune L, Davies I, Little RA, Horan MA & Kirkman E (2001). Cardiovascular response to graded lower body negative pressure in young and elderly man. *Exp Physiol* **86**, 427-435.

Ward KR, Tiba MH, Ryan KL, Filho IP, Rickards CA, Witten T, Soller BR, Ludwig DA & Convertino VA (2010). Oxygen transport characterization of a human model of progressive hemorrhage. *Resuscitation* **81**, 987-993.

Wesseling KH, Jansen JR, Settels JJ & Schreuder JJ (1993). Computation of aortic flow from pressure in humans using a nonlinear, three-element model. *J Appl Physiol* (1985) **74**, 2566-2573.

Williams J (2008). Revising the Declaration of Helsinki. *World Med J* **54**, 120-122.

Yanagawa Y, Sakamoto T & Okada Y (2005). Lymphocytosis without anemia in a patient presenting with anaphylactic shock. *Am J Emerg Med* **23**, 763-766.

Zaar M, Morkeberg J, Pott FC, Johansson PI & Secher NH (2014). Coagulation competence and fluid recruitment after moderate blood loss in young men. *Blood Coagul Fibrinolysis* **25**, 592-596.

Figure 1.




Figure 2.




Figure 3.





Figure 4.



Cerebral blood velocity regulation during progressive blood loss compared to lower body negative pressure in humans

Caroline A. Rickards¹, Blair D. Johnson², Ronée E. Harvey², Victor A. Convertino³, Michael J. Joyner² and Jill N. Barnes^{2,4}.

¹Department of Integrative Physiology & Anatomy and Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, TX; ²Department of Anesthesiology, Mayo Clinic, Rochester, MN; ³US Army Institute of Surgical Research, Fort Sam Houston, TX; ⁴Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN.

Running Title: Cerebral blood velocity and simulated hemorrhage

Manuscript word count: 4516

Abstract word count: 276

Number of figures: 5

Address for Correspondence:

Caroline A. Rickards, Ph.D.
Department of Integrative Physiology & Anatomy
University of North Texas Health Science Center
3500 Camp Bowie Boulevard
Fort Worth, TX 76107
Phone: 817-735-2735
Email: caroline.rickards@unthsc.edu

38 Abstract

39 Lower body negative pressure (LBNP) is often used to simulate blood loss in humans. It is
40 unknown if cerebral blood flow responses to actual blood loss are analogous to simulated blood
41 loss during LBNP. Nine healthy men were studied at baseline, during 3 levels of LBNP (5-min at -
42 15, -30, -45 mmHg), and during 3 levels of blood loss (333, 667, 1000 ml). LBNP and blood loss
43 conditions were randomized. Intra-arterial mean arterial pressure (MAP) was similar during
44 LBNP compared with blood loss ($p \geq 0.42$). Central venous pressure (CVP; 2.8 ± 0.7 vs. 4.0 ± 0.8 ,
45 1.2 ± 0.6 vs. 3.5 ± 0.8 , 0.2 ± 0.9 vs. 2.1 ± 0.9 mmHg for level 1, 2, and 3; $p \leq 0.003$) and stroke volume
46 (71 ± 4 vs. 80 ± 3 , 60 ± 3 vs. 74 ± 3 , 51 ± 2 vs. 68 ± 4 ml for level 1, 2, and 3; $p \leq 0.002$) were lower
47 during LBNP compared with blood loss. Despite differences in CVP, middle cerebral artery
48 velocity (MCAv) and cerebrovascular conductance (CVC) were similar between LBNP and blood
49 loss at each level (MCAv at level 3: 62 ± 6 vs. 66 ± 5 cm/s; $p = 0.37$; CVC at level 3: 0.72 ± 0.05 vs.
50 0.73 ± 0.05 cm/s/mmHg; $p = 0.53$). While the slope of the relationship between MAP and MCAv
51 was slightly different between LBNP and blood loss (LBNP: 0.41 ± 0.03 cm/s/mmHg vs. Blood
52 Loss: 0.66 ± 0.04 cm/s/mmHg; $P = 0.05$), time domain gain between MAP and MCAv at maximal
53 LBNP/blood loss ($P = 0.23$), and low frequency MAP-mean MCAv transfer function coherence,
54 gain and phase were similar ($P \geq 0.10$). Our results suggest that cerebral hemodynamic
55 responses to LBNP to -45 mmHg and blood loss up to 1000 ml follow a similar trajectory, and
56 the relationship between arterial pressure and cerebral blood velocity are not altered from
57 baseline under these conditions.

58 **Key Words:** simulated hemorrhage, cerebrovascular, hypovolemia

59 Introduction

60 Hemorrhage accounts for approximately one-third of all trauma related deaths (28), and 80% of
61 potentially survivable battlefield injuries (15). As logistical and ethical constraints have often
62 limited comprehensive assessment of the physiological responses to hemorrhage in humans,
63 studies investigating the early detection and prevention of blood loss in humans have often
64 used lower body negative pressure (LBNP) to simulate the hemodynamic effects of actual blood
65 loss. LBNP elicits progressive reductions in central blood volume, reflected by decreases in
66 central venous pressure (CVP), stroke volume (SV), and cardiac output (CO), eliciting baroreflex-
67 mediated increases in heart rate (HR) and total vascular resistance, and the release of
68 vasoactive and volume regulating hormones (11, 13, 18, 26, 35, 46, 47, 53). As reviewed by
69 Cooke et al., in 2004, many of these hemodynamic adjustments associated with LBNP are
70 similar to those induced by hemorrhage (13). While many studies have assessed the effects of
71 blood loss on hemodynamic responses in humans, such as arterial pressure, HR, SV,
72 sympathetic nerve activity and peripheral resistance (1, 2, 19, 39, 45, 50), few have
73 investigated cerebral blood flow responses (7, 48). Inadequate cerebral blood flow and
74 oxygenation is the final common pathway to loss of consciousness from blood loss, so
75 represents an important area of investigation. Two studies (7, 48) have demonstrated
76 progressive reductions in cerebral oxygenation assessed via near infrared spectroscopy (NIRS),
77 following withdrawal of ≤ 500 ml of blood. No studies, to our knowledge, have investigated
78 *cerebral blood flow* (or velocity) responses to hemorrhage of any magnitude in humans, or
79 whether the effects of actual blood loss on cerebral blood flow regulation are analogous to
80 simulated blood loss during LBNP.

A direct comparison of the physiological responses to LBNP and blood loss has been performed in a baboon model (21), and from these data, the estimated loss of blood in humans was calculated; approximately -70 mmHg LBNP equated to blood loss of 17.8 ml/kg, or ~0.25 ml/kg/mmHg LBNP. This study provided the basis for our work comparing simulated hemorrhage using LBNP with actual blood loss in adult men (25). While 1000 ml of blood loss elicited smaller reductions in CVPSV compared with -45 mmHg LBNP, between baseline and a loss of ~18% of total blood volume, the CVP, SV, HR, and mean arterial pressure (MAP) responses between LBNP and blood loss were linearly related (25). Importantly, this suggests that the hemodynamic responses to central hypovolemia associated with LBNP are similar to blood loss in adult men.

During progressive central hypovolemia using LBNP, middle cerebral artery velocity (MCAv) is initially maintained, followed by a progressive decrease until the onset of presyncope (3, 29, 41). As the inability to maintain adequate cerebral blood flow and oxygenation can determine tolerance to central hypovolemia (7, 29), the purpose of the present study was to compare the effects of actual graded blood loss to simulated hemorrhage using progressive LBNP on cerebral blood flow (velocity) regulation in humans.

Methods

Subjects. Nine healthy males were recruited for this study (age 31 ± 6 years; height 183 ± 7 cm; weight 89 ± 9 kg; body mass index 26.7 ± 1.8 kg/m²). These subjects were a sub-set of the 12 subjects reported in another publication focused on hemodynamic and hormonal responses to

this protocol (25). All subjects reported to be free of any cardiovascular, respiratory, neurologic, or metabolic disease. Subjects were non-obese ($\text{BMI} < 30 \text{ kg/m}^2$), non-smokers, and were not taking any medication. Prior to the study day, all subjects provided written informed consent after all procedures and risks of the study were fully explained; the study was approved by the Mayo Clinic Institutional Review Board. Subjects reported to the Clinical Research Unit at Mayo Clinic at 0700 following an overnight fast. At this time, each subject consumed a small breakfast bar (Clif Bar; Shelton, CT, USA; 240 kcals) and drank 250 ml of water. Subjects were studied in the supine position in a temperature controlled room ($20\text{-}22^\circ \text{C}$). To ensure subject safety, a board-certified anesthesiologist was present throughout the study day and a member of the Mayo Clinic autologous transfusion team was in attendance during the protocol.

Experimental Design. LBNP and blood loss protocols were performed on the same day in a counter-balanced order. Figure 1 illustrates the study protocol. The goal of the experimental design was to elicit a wide range of CVP in both protocols. Based on approximations for comparing LBNP levels to blood loss (13), we chose the initial stages of the U.S. Army Institute for Surgical Research LBNP protocol (-15 , -30 , and -45 mmHg chamber pressure) and stepwise reductions in blood volume that would closely mirror CVP at each stage ($3 \times 333 \text{ ml}$ aliquots of blood). Because the order of the protocols was mixed, we were unable to closely match CVP values between LBNP and blood loss as per the Hinojosa-Laborde et al., study in baboons where LBNP always followed blood loss (21). Either protocol was terminated early if: 1) MAP fell by 30% compared with baseline MAP 2) systolic blood pressure dropped

below 80 mmHg; or 3) the subject began to experience symptoms of pre-syncope or syncope. Hematocrit was measured from arterial blood samples collected during the baseline period and at the termination of each experimental protocol.

Measurements and Procedures.

Hemodynamic Monitoring. Subjects were positioned in the supine posture on an adjustable bed. A 3-lead electrocardiogram (ECG) was used to continuously record HR (Cardiacap/5, Datex-Ohmeda, Louisville, CO, USA). Arterial oxygen saturation was monitored using a finger pulse oximeter and end-tidal CO₂ (ETCO₂) was collected from a nasal cannula (Cardiacap/5, Datex-Ohmeda, Louisville, CO, USA). A 20-gauge, 5 cm catheter was placed into the brachial artery under local anesthesia (2% lidocaine) using aseptic techniques and ultrasound guidance. The catheter was attached to a high-resolution transducer positioned at heart level to obtain continuous brachial arterial pressure waveforms. Continuous hemodynamic, oxygen saturation, and ETCO₂ tracings were interfaced with a data acquisition system for offline analysis (WinDaq, DATAQ Instruments, Akron, OH, USA).

Cerebral blood velocity. Subjects were imaged using a 2-MHz Doppler probe (Transcranial Doppler (TCD), Neurovision System, Multigon, Yonkers, NY, USA) to estimate middle cerebral artery blood velocity (MCAv). The basal portion of the left MCA was insonated by placing the probe over the temporal bone just above the zygomatic arch in front of the ear. The Doppler signal was optimized by varying the sample volume depth in incremental steps and varying the angle of insonation to obtain the best-quality signal. Once the optimal signal was

determined, the probe was secured with a headband device to maintain a constant angle throughout the protocol.

Central venous pressure. A 16-gauge central catheter was introduced into an antecubital vein under local anesthesia (2% lidocaine) using aseptic techniques and advanced to the superior vena cava prior to its junction with the right atrium. This catheter was connected to a high-resolution transducer (FloTrac, Edwards Lifesciences Corp., Irvine, CA, USA) positioned at heart level and interfaced with a personal computer for continuous measurement of CVP. Correct placement of the peripherally inserted central catheter was visually confirmed by two anesthesiologists using the CVP waveform.

Blood removal. A 14-gauge catheter was placed in an antecubital vein to facilitate blood removal for the blood loss protocol. The catheter was placed under local anesthesia (2% lidocaine) using aseptic techniques. Preservative/anticoagulant bags (63 mL anti-coagulant citrate phosphate dextrose solution) were placed below the level of the bed to allow blood to transfer from the subject to the blood collection bags via gravity. In two subjects, a blood pressure cuff was inflated around the upper arm to 40 mmHg to enhance the rate of blood removal; this cuff pressure was released during all subsequent hemodynamic measurements. As blood was being collected, it was weighed to determine the volume of blood removed by multiplying the weight of the blood by a factor of 1.06 ml/g. The removed blood was kept in the study room (20-22°C), the temperature of the blood was allowed to fluctuate, and the collection bags were periodically agitated to prevent clotting.

Blood loss protocol. Following a 5 min baseline period, 3 aliquots of 333 ml of blood was removed as described. A 5 min measurement period separated each aliquot. Subjects were not allowed to cross their legs and were instructed to refrain from contracting lower body muscles throughout the protocol. At the end of the protocol, all shed blood was re-infused at a rate of 20 ml/min into the antecubital vein. Subjects rested quietly in the supine position for 45-75 min between protocols.

LBNP protocol. Subjects were supine in an airtight LBNP chamber that was sealed at the iliac crest and covered the lower body. The LBNP protocol was based on the first 3 stages of a commonly used protocol (8-10, 20, 41, 42) consisting of a 5 min baseline period followed by 5 min at -15, -30, and -45 mmHg of chamber decompression. Subjects were not allowed to cross their legs and were instructed to refrain from contracting lower body muscles throughout the protocol.

Data and Statistical Analysis. Data was collected at 500 Hz (WinDaq, DATAQ Instruments, Akron, OH, USA) and stored on a laboratory computer for off-line analysis with signal processing software (WinDaq, DATAQ Instruments, Akron, OH, USA; WinCPRS, Absolute Aliens, Turku, Finland). All variables of interest (HR, blood pressure, CVP, ETCO₂, and MCAv) were continuously monitored throughout both protocols and data were analyzed and averaged over the last 3 min of each stage for statistical analysis. MAP and mean MCAv were calculated as the area under the arterial pressure and MCAv curves. SV was calculated using specialized analysis software (WinCPRS, Absolute Aliens, Turku, Finland) based on the brachial arterial pressure

waveform (23). CO was derived using the calculated SV and HR obtained by ECG. A portion of this hemodynamic data is presented in a publication for N=12 (25), specifically the HR, MAP, SV, CO, and CVP responses. Cerebrovascular conductance (CVC) was calculated as $MCAv/MAP$. The gain between changes in mean MCAv and MAP was calculated to assess arterial pressure-cerebral blood velocity relationships in the time domain at the maximal level of LBNP/blood loss for each subject.

Arterial pressure-cerebral blood velocity relationships were also explored via transfer function analysis. Beat-to-beat time domain MAP and mean MCAv waveforms were processed with a fast Fourier transform. Data were made equidistant by interpolating linearly and resampling at 5 Hz. Data were then passed through a low-pass filter with a cutoff frequency of 0.5 Hz. Three-minute data sets were fast Fourier transformed with a Hanning window to obtain power spectra. Spectral power was expressed as the integrated area within the very low frequency (VLF) range of 0.004–0.04 Hz, and low frequency (LF) range of 0.04–0.15 Hz. We calculated the coherence between MAP and mean MCAv by dividing the squared cross-spectral densities of the two signals by the product of the individual autospectra. Transfer function gain and phase between MAP and mean MCAv represent a frequency dependence, and can be used to assess dynamic cerebral blood flow-pressure relationships (17, 54). Transfer function gain and phase were considered valid and averaged in the VLF and LF only when coherence values were ≥ 0.5 .

To explore the relationships between the physiological responses from the two protocols, the amalgamated r^2 value was calculated using linear regression analysis for each variable of interest (SV and CVP) for blood loss versus LBNP as per Johnson et al. (25). Linear mixed effect model analysis with repeated measures was used to assess the relationship between mean MCAv versus MAP across LBNP and blood loss for all subjects; ETCO₂ was also included as a co-variate due to the independent effects of arterial CO₂ on mean MCAv and MAP. Condition $\times$ stage (2×4) repeated measures ANOVAs were used to determine if values obtained during the LBNP protocol were similar to the corresponding stages of the blood loss protocol. A one-way repeated measures ANOVA was used to compare the time of blood withdrawal across the 3 aliquots. If a significant main or interaction effect was detected, Tukey's post hoc analyses were performed to determine where differences existed. Paired t-tests were used to compare hematocrit responses within the LBNP or hemorrhage protocols, and maximal MAP-mean MCAv gain responses between conditions. Group data are presented as mean $\pm$ SE, unless otherwise stated. Exact P-values are reported.

Results

All nine subjects performed both trials. Due to presyncopal symptoms, one subject did not complete the last level of LBNP, one subject did not complete the last level of blood loss, and one subject did not complete the last level of either trial. The mean time for blood removal was 563 ± 49 sec for the first 333 ml, 489 ± 56 sec for the second 333 ml, and 467 ± 73 sec for the final 333 ml ($P=0.195$). Hematocrit increased with LBNP (baseline: $40.6 \pm 0.9\%$ vs.

227 termination: 41.9 ± 0.9 ; $P=0.020$) and decreased with hemorrhage (baseline: $40.8 \pm 0.9\%$ vs.
228 termination: 39.7 ± 0.9 ; $P=0.001$). Hemodynamic responses are shown in Table 1. MAP
229 decreased between baseline and level 3 only during the LBNP trial ($P=0.001$). There were no
230 differences in MAP between the LBNP and blood loss trials at any level ($P\geq 0.42$). At each level,
231 CVP decreased below baseline in both LBNP and blood loss protocols, but values were
232 consistently higher during blood loss compared with LBNP ($P\leq 0.003$). During the LBNP trial, SV
233 and CO were lower than baseline at every level, but for the blood loss trial SV was reduced
234 during level 2 and 3 only and CO did not decrease below baseline values. Consistent with the
235 CVP responses, SV and CO were higher during the blood loss vs. LBNP trial at each level of the
236 protocol, except baseline. HR was higher than baseline for levels 2 and 3 of LBNP and during
237 level 3 of blood loss; in response to the greater reduction in central blood volume, HR was
238 higher during levels 2 and 3 of the LBNP trial compared with the blood loss trial. The CVP and
239 SV responses during LBNP versus blood loss are presented in figure 2; both amalgamated r^2
240 values were ≥ 0.80 , but the slopes were < 0.6 , reflecting the differences in central blood volume
241 reduction between conditions.

242 Cerebral blood velocity and CVC responses to LBNP and blood loss are shown in table 1.
243 Mean MCAv decreased by $11\pm 3\%$ and $3\pm 4\%$ for the LBNP and blood loss protocols ($P=0.44$), but
244 was statistically distinguishable from baseline at the final level of the LBNP protocol only
245 ($P=0.002$). CVC did not change, and responses were similar between LBNP and blood loss trials
246 ($P\geq 0.47$). ETCO_2 decreased at level 3 for the blood loss trial only, and respiration rate
247 decreased for the LBNP trial only.

Individual mean MCAv vs. MAP responses are presented in figure 3. There was inter-subject variability in these responses, and as a group, the slope of the line between MCAv and MAP was lower with LBNP compared with blood loss (LBNP: 0.41 ± 0.03 cm/s/mmHg vs. blood loss: 0.66 ± 0.04 cm/s/mmHg; $P=0.05$). The time domain gain between maximal changes in mean MCAv and MAP was similar between LBNP and blood loss (1.2 ± 0.2 cm/s/mmHg vs. 4.3 ± 2.4 cm/s/mmHg; $P=0.23$). LF and VLF power spectral density (PSD) for MAP and mean MCAv are shown in figure 4. There were no differences from baseline ($P \geq 0.13$) in PSD for MAP LF and VLF, or MCAv LF and VLF in either trial, or in these responses between the LBNP and blood loss conditions ($P \geq 0.23$). Similarly, there was no effect of condition or level for MAP-MCAv LF coherence, gain, or phase ($P \geq 0.10$; figure 5). VLF coherence was consistently < 0.5 for both conditions across all levels, so phase and gain are not reported.

Discussion

This is the first study to systematically compare cerebral blood velocity responses between LBNP and actual hemorrhage in healthy human subjects. The key findings from this investigation are; 1) LBNP up to -45 mmHg elicited greater reductions in central blood volume than hemorrhage up to ~1000 ml (as indicated by comparisons of SV, CO, and CVP); 2) the subsequent cerebral blood velocity responses reflected these differences in central blood volume, but the trajectories of the cerebral blood velocity and cerebrovascular conductance responses were similar between LBNP and blood loss conditions; and, 3) neither the LBNP nor

blood loss protocols induced changes in the relationship between MAP and mean MCAv as determined by gain calculations in both the time domain and via transfer function analysis.

In 1940, Ebert and Stead reported the sequestration of approximately 15% of total blood volume into the extremities (two legs and one arm) following rapid application of tourniquets as a potential alternative to phlebotomy for the treatment of congestive heart failure (16). Over 20 years later, a number of investigators introduced LBNP as a method to further decrease central blood volume to simulate the cardiovascular effects of hemorrhage and orthostasis (6, 46). Direct comparison of the hemodynamic responses to LBNP and removal of 450 ml of blood from human volunteers (i.e., one unit) suggested equivalency between one unit of blood loss and -10 to -20 mmHg LBNP determined by reductions in CVP (39) and SV (19), and subsequent reflex increases in sympathetic nerve activity (39). Recently, studies comparing the cardiovascular and neurohumoral responses to LBNP and blood loss of greater than one unit (i.e., >500 ml) were performed in baboons (21) and in humans (25). Based on the results reported by Hinojosa-Laborde et al. (21), LBNP elicits a reduction in central blood volume (indexed by SV) of ~0.25 ml/kg/mmHg LBNP, equating to blood loss of approximately 450, 1000, and 1600 ml with LBNP of -30, -60, and -90 mmHg in a 70 kg human.

While protection of cerebral perfusion and oxygenation is essential for maintaining consciousness under hypotensive conditions of actual or simulated hemorrhage, few studies have measured these responses to actual blood loss, and none have compared responses between blood loss and LBNP. In two studies assessing cerebral oxygen saturation responses (via NIRS) to blood loss protocols of ≤500 ml, Colier et al., (7) and Torella et al., (48) reported

289 increases in deoxy-hemoglobin concentration, and decreases in oxy-hemoglobin concentration
290 and cerebral oxygen saturation. As NIRS measures a sample volume consisting of a mix of
291 approximately 25% arterial and 75% venous blood (33, 38), decreases in oxy-hemoglobin and
292 increases in deoxy-hemoglobin suggest an increase in oxygen extraction, most likely to
293 compensate for reduced blood flow supplying the cerebral tissues; measures of cerebral blood
294 flow (or velocity), however, were not reported in either of these investigations. The current
295 study is the first, to our knowledge, to report cerebral blood velocity responses to actual
296 hemorrhage (up to ~1000 ml) in humans, and to compare these responses to LBNP. As
297 reported for a larger group of subjects (N=12) (25), LBNP to -45 mmHg elicits greater reductions
298 in central blood volume than 1000 ml of blood loss. As a consequence, mean MCAv was
299 reduced by ~11% with LBNP compared with a decrease of just ~3% with blood loss, MAP
300 decreased by ~8% (LBNP) and ~2% (blood loss), and the relationship between mean MCAv and
301 MAP was lower for LBNP compared with blood loss (figure 3). We speculate that continued
302 blood loss would eventually elicit similar cerebral blood velocity responses between conditions.
303 Based on the cerebral blood velocity data presented in table 1 and figure 3, and the
304 hemodynamic data presented by Johnson et al., (25), 1000 ml of blood loss implemented in the
305 present protocol appears equivalent to LBNP of between -15 to -30 mmHg. This is in contrast
306 to estimations using SV responses from baboons exposed to both LBNP and hemorrhage (0.25
307 ml/kg/mmHg, as described previously) (21), where -45 mmHg LBNP would be equivalent to
308 1000 ml of blood loss in the subjects used in the present investigation (i.e., body weight of
309 approx. 90 kg). Prospective matching of both CVP responses and the time course of blood
310 withdrawal and LBNP exposure between the two protocols, as per Hinojosa-Laborde et al., (21)

may address these differences in central hypovolemia observed in the current investigation, and allow for more accurate calculations of equivalency.

LF oscillatory power for both MAP and mean MCAv did not change from baseline under either LBNP or blood loss conditions. The stability of MAP LF was unexpected based on previously observed increases in MAP LF with LBNP of similar magnitude and duration (4, 5, 41, 55). LF oscillations in arterial pressure are primarily modulated by the baroreflex, evidenced by a strong association with LF power in muscle sympathetic nerve activity (MSNA), which in turn, is related to higher absolute MSNA (12, 27). As such, baroreflex-mediated sympathoexcitation with LBNP-induced hypotension increases MSNA, and LF power in both MSNA and arterial pressure (12). The very mild reductions in MAP (-8 and -2 mmHg) by the final level of LBNP and blood loss in the current study may not have been sufficient to elicit increases in MSNA, hence there was no increase in MSNA LF or, subsequently, MAP LF. This speculation is supported, in part, by an increase in circulating norepinephrine only with LBNP and not blood loss as reported by Johnson et al., (25). The small subject number combined with high inter-subject variability in MAP LF responses under both protocols also contribute to this finding. As oscillations in arterial pressure are the primary driving factor for increased MCAv oscillations, it is not surprising that MCAv LF power did not change under either protocol.

Assessing the relationship between arterial pressure and cerebral blood velocity oscillations via transfer function analysis in the VLF and LF ranges has been interpreted as an index of cerebral autoregulation (54). The low coherence between MAP and mean MCAv in the VLF (<0.5) across time and condition indicates an independence of flow from pressure within

this frequency range (54). While coherence between MAP and mean MCAv was consistently > 0.5 in the LF range, transfer function gain and phase did not change with either LBNP or blood loss, and were not different between conditions. These findings are in contrast with a number of studies that show either a reduction (41) or increase (55) in MAP-mean MCAv gain during LBNP of similar magnitude. In particular, Zhang et al., (55) suggested that simultaneous increases in the magnitude of oscillations in both arterial pressure and cerebral blood velocity and the subsequent increase in MAP-mean MCAv gain, represented attenuated cerebral autoregulation, that may, in turn, predispose individuals to presyncope. The stability of MAP-mean MCAv gain and phase reported in the current investigation is most likely associated with the stability of MAP and mean MCAv LF oscillations, and the high inter-subject variability inherent in transfer function estimates of cerebral pressure-flow relationships, further compounded by the small sample size utilized in this study. In the time domain, cerebral autoregulation can also be assessed as the gain between changes in arterial pressure and cerebral blood velocity (36, 40); in the present study this relationship was not altered under either condition, and was not statistically distinguishable between conditions. Together, these data suggest that cerebral pressure-flow relationships across multiple time scales (fast component via transfer function analysis and slow component via time domain analysis) were not affected by the magnitude of central hypovolemia induced by either LBNP or blood loss. Other factors, including small reductions in arterial CO₂ and increased sympathetic drive may also be contributing to the observed small decrease in MCAv with LBNP and blood loss.

Methodological Considerations

Many of the key methodological considerations associated with the design of this study have been addressed by Johnson et al., (25) including removal of absolute blood volumes (i.e., 333, 666, 1000 ml) rather than a percentage of total blood volume, the inability to match CVP responses due to the random order of the protocols, restricting exposure to LBNP and blood loss to sub-maximal levels, differences in the time course of blood removal versus LBNP exposure, and inclusion of only male subjects. There are some additional issues specific to the data included in this study that should be considered.

As we used TCD for assessment of cerebral blood velocity within the MCA, we assume the measurement of velocity is equivalent to flow as long as the caliber of the MCA does not change over the course of the intervention. While recent studies have indicated changes in MCA cross sectional area (CSA) with both increases ($\text{ETCO}_2 \geq 9$ mmHg above baseline) and decreases in arterial CO_2 ($\text{ETCO}_2 \geq 13$ mmHg below baseline) (14, 49), the magnitude of hypocapnia induced with both LBNP and blood loss in the current investigation (2-3 mmHg below baseline) was well below these levels. Additionally, sympathoexcitation with the hypotensive stimuli of both LBNP and blood loss could result in cerebral vasoconstriction, which may also invalidate the assumption of constant arterial diameter. MCA diameter is constant, however, with LBNP up to -40 mmHg (44), and the mild hypotensive stimulus elicited with both LBNP and blood loss in the current study render this limitation unlikely. Future assessment of cerebral blood flow of the extracranial feeding arteries (e.g., internal carotid artery, vertebral artery) (22, 37, 43, 52), and/or use of transcranial color-coded Doppler (TCCD) ultrasound (34, 51) during this type of investigation would allow for direct assessment of cerebral blood flow without relying on the assumption of constant arterial caliber. Furthermore, recent

investigations have revealed potential regional differences in cerebral blood flow regulation, where the posterior circulation may be more sensitive to hypotension and hypocapnia compared with the anterior circulation (31), indicating inclusion of these measurements in future studies.

While maintenance of cerebral blood flow is crucial for the delivery of oxygen to the cerebral tissues, the ability of the brain to extract and utilize this oxygen may be of greater importance. This issue has been highlighted by a number of studies demonstrating that protection of absolute cerebral blood flow (or velocity) does not necessarily provide insight about tolerance to central hypovolemia (24, 30, 32, 41). Inclusion of cerebral oxygenation, oxygen extraction, and/or cerebral oxygen metabolism measurements would be valuable additions to comparisons of LBNP and hemorrhage to address this important issue.

Conclusion

The findings from the present investigation indicate that cerebral blood velocity responses to central hypovolemia induced by LBNP to -45 mmHg and actual blood loss up to 1000 ml follow a similar trajectory, and the relationship between arterial pressure and cerebral blood velocity are not altered under these conditions. Careful matching of both the magnitude of central hypovolemia (e.g., via CVP) and time course of blood loss vs. LBNP exposure, and inclusion of additional cerebral blood flow and oxygenation measurements in future studies will facilitate a more comprehensive understanding of these responses. This study represents an important step in understanding cerebral blood flow responses to hemorrhage, and provides

397 evidence for the continued use of LBNP as a model of hemorrhage in healthy, conscious
398 volunteer subjects.

399

400 **Acknowledgements**

401 The authors would like to thank Shelly Roberts, Sarah Wolhart, Timothy Curry, John Eisenach,
402 Christopher Johnson, Pamela Engrav, Branton Walker, Jennifer Taylor, and Luke Matzek for
403 their continued assistance throughout the project, and Yu Chieh Tzeng, Ph.D. for his valuable
404 advice on the linear mixed effect models analysis. The views, opinions, and/or findings
405 contained in this article are those of the authors and should not be construed as an official
406 Department of the Army position, or decision, unless so designated by other official
407 documentation. Approved for public release; distribution unlimited.

408

409 **Sources of Funding**

410 Funding provided by U.S. Army MPMC Combat Casualty Care Research Program Grants #
411 W81XWH-11-1-0823 (MJJ) and # W81XWH-11-2-0137 (CAR), NIH AG038067 (JNB), American
412 Heart Association Midwest Affiliate Grants 13POST-14380027 (BDJ) and 14PRE-18040000 (REH).
413 *"This publication was made possible by CTSA Grant Number **UL1 TR000135** from the National*
414 *Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of*
415 *Health (NIH), and from the US Army. Its contents are solely the responsibility of the authors and*
416 *do not necessarily represent the official view of NIH, the Department of the Army, or the*
417 *Department of Defense."*

418

419 **Conflict of Interest**

420 None.

421

422 **Figure Legends**

423 **Figure 1.** Study protocol. Lower body negative pressure (LBNP) and blood loss conditions were
424 counterbalanced. The duration of the rest period between LBNP and blood loss depended on
425 which one was performed first, with more time required after the blood loss protocol.

426 **Figure 2.** Linear regression for amalgamated values for central venous pressure (CVP, Panel A),
427 and stroke volume (SV, Panel B) responses between lower body negative pressure (LBNP) and
428 blood loss conditions.

429 **Figure 3.** Individual plots of mean arterial pressure (MAP) versus mean middle cerebral artery
430 velocity (MCAv) for all 9 subjects for LBNP (blue circles) and blood loss (red circles). Group
431 responses are presented in the lower right panel (N=9).

432 **Figure 4.** Low frequency (LF) and very low frequency (VLF) power spectral density for mean
433 arterial pressure (MAP; Panels A and C), mean middle cerebral artery velocity (MCAv; Panels B
434 and D) during lower body negative pressure (LBNP) and blood loss. Data are mean $\pm$ SE.

435 **Figure 5.** Low frequency (LF) coherence, phase and gain between mean arterial pressure
436 (MAP) and mean middle cerebral artery velocity (MCAv) during lower body negative pressure
437 (LBNP) and blood loss. Data are mean $\pm$ SE.

438

439 **Tables**440 **Table 1** Physiological Responses to LBNP and Blood Loss

Hypovolemic stress	Baseline	Level 1	Level 2	Level 3
<i>LBNP (mmHg)</i>	--	-15	-30	-45
<i>Blood Loss (mL)</i>	--	-333	-667	-1000
MAP, mmHg				
• LBNP	94 ± 3	91 ± 3	87 ± 5	86 ± 4 [†]
• Blood Loss	93 ± 3	92 ± 2	90 ± 3	91 ± 3
CVP, mmHg				
• LBNP	7.4 ± 0.9	2.8 ± 0.7 [†]	1.2 ± 0.6 [†]	0.2 ± 0.9 [†]
• Blood Loss	6.5 ± 0.8	4.0 ± 0.8 ^{*†}	3.5 ± 0.8 ^{*†}	2.1 ± 0.9 ^{*†}
SV, mL				
• LBNP	81 ± 4	71 ± 4 [†]	60 ± 3 [†]	51 ± 2 [†]
• Blood Loss	85 ± 5	80 ± 3 [*]	74 ± 3 ^{*†}	68 ± 4 ^{*†}
HR, beats/min				
• LBNP	57 ± 3	60 ± 2	67 ± 3 [†]	76 ± 4 [†]
• Blood Loss	57 ± 3	58 ± 2	61 ± 2 [*]	65 ± 3 ^{*†}
CO, L/min				
• LBNP	4.6 ± 0.3	4.2 ± 0.2 [†]	3.9 ± 0.2 [†]	3.8 ± 0.2 [†]
• Blood Loss	4.8 ± 0.3	4.7 ± 0.3 [*]	4.5 ± 0.2 [*]	4.4 ± 0.3 [*]
Mean MCAv, cm/s				
• LBNP	70.0 ± 4.2	69.3 ± 4.3	65.2 ± 4.3	61.5 ± 5.8 [†]
• Blood Loss	69.5 ± 5.1	69.6 ± 5.3	67.7 ± 5.0	66.5 ± 5.2
CVC, cm/s/mmHg				
• LBNP	0.75 ± 0.04	0.77 ± 0.05	0.76 ± 0.05	0.72 ± 0.05
• Blood Loss	0.75 ± 0.04	0.75 ± 0.05	0.75 ± 0.04	0.73 ± 0.05
ETCO₂, mmHg				
• LBNP	40 ± 2	40 ± 2	39 ± 2	38 ± 3
• Blood Loss	41 ± 2	40 ± 2	39 ± 2	38 ± 3 [†]
Respiration rate, n				
• LBNP	15 ± 1	13 ± 1 [†]	13 ± 1 [†]	14 ± 1 [†]
• Blood Loss	13 ± 1 [*]	13 ± 1	13 ± 1	12 ± 1

441 Mean ± SEM. Data are calculated from the final 3-min of each level. MAP=mean arterial
442 pressure; CVP=central venous pressure; SV=stroke volume; HR=heart rate; CO=cardiac output;
443 MCAv=middle cerebral artery velocity; CVC=cerebral vascular conductance; ETCO₂=end-tidal
444 carbon dioxide. *p<0.05 vs. LBNP at the same level; †p<0.05 vs. baseline of the same protocol.

1. **Barcroft H, Edholm OG, McMichael J, and Sharpey-Schafer EP.** Posthaemorrhagic fainting study by cardiac output and forearm flow. *Lancet* i: 489-491, 1944.
2. **Bassin R, Vladeck BC, Kark AE, and Shoemaker WC.** Rapid and slow hemorrhage in man. I. Sequential hemodynamic responses. *Ann Surg* 173: 325-330, 1971. 1397391.
3. **Bondar RL, Kassam MS, Stein F, Dunphy PT, Fortney S, and Riedesel ML.** Simultaneous cerebrovascular and cardiovascular responses during presyncope. *Stroke* 26: 1794-1800, 1995.
4. **Brown CM, Dutsch M, Hecht MJ, Neundorfer B, and Hilz MJ.** Assessment of cerebrovascular and cardiovascular responses to lower body negative pressure as a test of cerebral autoregulation. *J Neurol Sci* 208: 71-78, 2003.
5. **Brown CM, Dutsch M, Ohring S, Neundorfer B, and Hilz MJ.** Cerebral autoregulation is compromised during simulated fluctuations in gravitational stress. *Eur J Appl Physiol* 91: 279-286, 2004.
6. **Brown E, Goei JS, Greenfield AD, and Plassaras GC.** Circulatory responses to simulated gravitational shifts of blood in man induced by exposure of the body below the iliac crests to sub-atmospheric pressure. *J Physiol* 183: 607-627, 1966. PMC1357510.
7. **Colier WN, Binkhorst RA, Hopman MT, and Oeseburg B.** Cerebral and circulatory haemodynamics before vasovagal syncope induced by orthostatic stress. *Clin Physiol* 17: 83-94, 1997.
8. **Convertino VA, Grudic G, Mulligan J, and Moulton S.** Estimation of individual-specific progression to impending cardiovascular instability using arterial waveforms. *Journal of applied physiology (Bethesda, Md : 1985)* 115: 1196-1202, 2013.
9. **Convertino VA, Rickards CA, Lurie KG, and Ryan KL.** Hyperventilation in response to progressive reduction in central blood volume to near syncope. *Aviat Space Environ Med* 80: 1012-1017, 2009.
10. **Convertino VA, Ryan KL, Rickards CA, Cooke WH, Metzger A, Holcomb JB, Adams BD, and Lurie KG.** Inspiratory resistance maintains arterial pressure during central hypovolemia: implications for treatment of patients with severe hemorrhage. *Crit Care Med* 35: 1145-1152, 2007.
11. **Convertino VA, and Sather TM.** Vasoactive neuroendocrine responses associated with tolerance to lower body negative pressure in humans. *Clin Physiol* 20: 177-184, 2000.
12. **Cooke WH, Rickards CA, Ryan KL, Kuusela TA, and Convertino VA.** Muscle sympathetic nerve activity during intense lower body negative pressure to presyncope in humans. *J Physiol (Lond)* 587: 4987-4999, 2009. PMC2770161.
13. **Cooke WH, Ryan KL, and Convertino VA.** Lower body negative pressure as a model to study progression to acute hemorrhagic shock in humans. *J Appl Physiol* 96: 1249-1261, 2004.
14. **Coverdale NS, Gati JS, Opalevych O, Perrotta A, and Shoemaker JK.** Cerebral blood flow velocity underestimates cerebral blood flow during modest hypercapnia and hypocapnia. *J Appl Physiol* 117: 1090-1096, 2014. PMID: 25012027.
15. **Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, Mallett O, Zubko T, Oetjen-Gerdes L, Rasmussen TE, Butler FK, Kotwal RS, Holcomb JB, Wade C, Champion H, Lawnick M, Moores L, and Blackbourne LH.** Death on the battlefield (2001-2011): Implications for the future of combat casualty care. *J Trauma Acute Care Surg* 73: S431-437, 2012.
16. **Ebert RV, and Stead EA.** The effect of the application of tourniquets on the hemodynamics of the circulation. *J Clin Invest* 19: 561-567, 1940. PMC434991.
17. **Giller CA.** The frequency-dependent behaviours of cerebral autoregulation. *Neurosurgery* 27: 362-368, 1990.
18. **Greenleaf JE, Petersen TW, Gabrielsen A, Pump B, Bie P, Christensen NJ, Warberg J, Videbaek R, Simonson SR, and Norsk P.** Low LBNP tolerance in men is associated with attenuated activation of the renin-angiotensin system. *Am J Physiol* 279: R822-829, 2000.
19. **Hanson JM, Van Hoeyweghen R, Kirkman E, Thomas A, and Horan MA.** Use of stroke distance in the early detection of simulated blood loss. *J Trauma* 44: 128-134, 1998.

20. **Hinojosa-Laborde C, Rickards CA, Ryan KL, and Convertino VA.** Heart Rate Variability during Simulated Hemorrhage with Lower Body Negative Pressure in High and Low Tolerant Subjects. *Front Physiol* 2: 85, 2011. 3221414.
21. **Hinojosa-Laborde C, Shade RE, Muniz GW, Bauer C, Goei KA, Pidcoke HF, Chung KK, Cap AP, and Convertino VA.** Validation of lower body negative pressure as an experimental model of hemorrhage. *J Appl Physiol* 116: 406-415, 2014. 4073981.
22. **Huang SY, Moore LG, McCullough RE, McCullough RG, Micco AJ, Fulco C, Cymerman A, Manco-Johnson M, Weil JV, and Reeves JT.** Internal carotid and vertebral arterial flow velocity in men at high altitude. *J Appl Physiol* 63: 395-400, 1987.
23. **Jellema WT, Imholz BPM, Van Goudoever J, Wesseling KH, and Van Lieshout JJ.** Finger arterial versus intrabrachial pressure and continuous cardiac output during head-up tilt testing in healthy subjects. *Clin Sci* 91: 193-200, 1996.
24. **Jeong SM, Shibata S, Levine BD, and Zhang R.** Exercise plus volume loading prevents orthostatic intolerance but not reduction in cerebral blood flow velocity after bed rest. *Am J Physiol Heart Circ Physiol* 302: H489-497, 2012.
25. **Johnson BD, van Helmond N, Curry TB, van Buskirk CM, Convertino VA, and Joyner MJ.** Reductions in central venous pressure by lower body negative pressure or blood loss elicit similar hemodynamic responses. *J Appl Physiol* 117: 131-141, 2014.
26. **Johnson JM, Rowell LB, Niederberger M, and Eisman MM.** Human splanchnic and forearm vasoconstrictor responses to reductions of right atrial and aortic pressures. *Circ Res* 34: 515-524, 1974.
27. **Julien C.** The enigma of Mayer waves: Facts and models. *Cardiovasc Res* 70: 12-21, 2006.
28. **Kauvar DS, Lefering R, and Wade CE.** Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. *J Trauma* 60: S3-11, 2006.
29. **Levine BD, Giller CA, Lane LD, Buckley JC, and Blomqvist CG.** Cerebral versus systemic hemodynamics during graded orthostatic stress in humans. *Circulation* 90: 298-306, 1994.
30. **Lewis NC, Bain AR, MacLeod DB, Wildfong KW, Smith KJ, Willie CK, Sanders ML, Numan T, Morrison SA, Foster GE, Stewart JM, and Ainslie PN.** Impact of hypocapnia and cerebral perfusion on orthostatic tolerance. *J Physiol* 592: 5203-5219, 2014.
31. **Lewis NC, Smith KJ, Bain AR, Wildfong KW, Numan T, and Ainslie PN.** Impact of transient hypotension on regional cerebral blood flow in humans. *Clin Sci (Lond)* 129: 169-178, 2015.
32. **Lucas RA, Pearson J, Schlader ZJ, and Crandall CG.** Hypercapnia-induced increases in cerebral blood flow do not improve lower body negative pressure tolerance during hyperthermia. *Am J Physiol Regul Integr Comp Physiol* 305: R604-609, 2013. PMC3763041.
33. **Madsen PL, and Secher NH.** Near-infrared oximetry of the brain. *Prog Neurobiol* 58: 541-560, 1999.
34. **Martin PJ, Evans DH, and Naylor AR.** Measurement of blood flow velocity in the basal cerebral circulation: advantages of transcranial color-coded sonography over conventional transcranial Doppler. *J Clin Ultrasound* 23: 21-26, 1995.
35. **Murray RH, Thompson LJ, Bowers JA, and Albright CD.** Hemodynamic effects of graded hypovolemia and vasodepressor syncope induced by lower body negative pressure. *Am Heart J* 76: 799-811, 1968.
36. **Novak V, Novak P, Spies JM, and Low PA.** Autoregulation of cerebral blood flow in orthostatic hypotension. *Stroke* 29: 104-111, 1998.
37. **Ogoh S, Sato K, Nakahara H, Okazaki K, Subudhi AW, and Miyamoto T.** Effect of acute hypoxia on blood flow in vertebral and internal carotid arteries. *Exp Physiol* 98: 692-698, 2013. PMID: 23143991.
38. **Pollard V, Prough DS, DeMelo AE, Deyo DJ, Uchida T, and Stoddart HF.** Validation in volunteers of a near-infrared spectroscopy for monitoring brain oxygenation in vivo. *Anesth Analg* 82: 269-277, 1996.

39. **Rea RF, Hamdan M, Clary MP, Randels MJ, Dayton PJ, and Strauss RG.** Comparison of muscle sympathetic responses to hemorrhage and lower body negative pressure in humans. *J Appl Physiol* 70: 1401-1405, 1991.
40. **Rickards CA, Cohen KD, Bergeron LL, Burton BL, Khatri PJ, Lee CT, Ryan KL, Cooke WH, Doerr DF, and Convertino VA.** Cerebral blood flow response and its association with symptoms during orthostatic hypotension. *Aviat Space Environ Med* 78: 653-658, 2007.
41. **Rickards CA, Ryan KL, Cooke WH, and Convertino VA.** Tolerance to central hypovolemia: the influence of oscillations in arterial pressure and cerebral blood velocity. *J Appl Physiol* 111: 1048-1058, 2011. PMID: 21799129.
42. **Ryan KL, Cooke WH, Rickards CA, Lurie KG, and Convertino VA.** Breathing through an inspiratory threshold device improves stroke volume during central hypovolemia in humans. *J Appl Physiol* 104: 1402-1409, 2008.
43. **Sato K, Fisher JP, Seifert T, Overgaard M, Secher NH, and Ogoh S.** Blood flow in internal carotid and vertebral arteries during orthostatic stress. *Exp Physiol* 97: 1272-1280, 2012.
44. **Serrador JM, Picot PA, Rutt BK, Shoemaker JK, and Bondar RL.** MRI measures of middle cerebral artery diameter in conscious humans during simulated orthostasis. *Stroke* 31: 1672-1678, 2000.
45. **Shenkin HA, Cheney RH, Govons SR, Hardy JD, and Fletcher AG.** On the diagnosis of hemorrhage in man - a study of volunteers bled large amounts. *Am J Med Sci* 208: 421-436, 1944.
46. **Stevens PM, and Lamb LE.** Effects of lower body negative pressure on the cardiovascular system. *Am J Cardiol* 16: 506-515, 1965.
47. **Summers RL, Ward KR, Witten T, Convertino VA, Ryan KL, Coleman TG, and Hester RL.** Validation of a computational platform for the analysis of the physiologic mechanisms of a human experimental model of hemorrhage. *Resuscitation* 80: 1405-1410, 2009. PMC3042239.
48. **Torella F, Cowley RD, Thorniley MS, and McCollum CN.** Regional tissue oxygenation during hemorrhage: can near infrared spectroscopy be used to monitor blood loss? *Shock* 18: 440-444, 2002.
49. **Verbree J, Bronzwaer AS, Ghariq E, Versluis MJ, Daemen MJ, van Buchem MA, Dahan A, Van Lieshout JJ, and van Osch MJ.** Assessment of middle cerebral artery diameter during hypocapnia and hypercapnia in humans using ultra high-field MRI. *J Appl Physiol* 117: 1084-1089, 2014. PMID: 25190741.
50. **Wallace JP, and Sharpey-Schafer EP.** Blood changes following controlled hemorrhage in man. *Lancet* 2: 393-395, 1941.
51. **Willie CK, Colino FL, Bailey DM, Tzeng YC, Binsted G, Jones LW, Haykowsky MJ, Bellapart J, Ogoh S, Smith KJ, Smirl JD, Day TA, Lucas SJ, Eller LK, and Ainslie PN.** Utility of transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function. *J Neurosci Methods* 196: 221-237, 2011. PMID: 21276818.
52. **Willie CK, Macleod DB, Shaw AD, Smith KJ, Tzeng YC, Eves ND, Ikeda K, Graham J, Lewis NC, Day TA, and Ainslie PN.** Regional brain blood flow in man during acute changes in arterial blood gases. *J Physiol* 590: 3261-3275, 2012. PMC3459041.
53. **Wolthuis RA, Bergman SA, and Nicogossian AE.** Physiological effects of locally applied reduced pressure in man. *Physiol Rev* 54: 566-595, 1974.
54. **Zhang R, Zuckerman JH, Giller CA, and Levine BD.** Transfer function analysis of dynamic cerebral autoregulation in humans. *Am J Physiol* 274: H233-241, 1998.
55. **Zhang R, Zuckerman JH, and Levine BD.** Deterioration of cerebral autoregulation during orthostatic stress: insights from the frequency domain. *J Appl Physiol* 85: 1113-1122, 1998.

FIGURE 1






FIGURE 2

















FIGURE 3

FIGURE 4


A



B



C



D






FIGURE 5


A



B



C



1
2
3 **Coagulation Changes during Lower Body Negative Pressure and Blood Loss in Humans**
4

5 Noud van Helmond^{1,2}, Blair D. Johnson^{1,3}, Timothy B. Curry¹, Andrew P. Cap⁴, Victor A.
6 Convertino⁴, & Michael J. Joyner¹
7

8 ¹Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota

9 ²Department of Physiology, Radboud University Nijmegen Medical Centre, Nijmegen, The
10 Netherlands

11 ³Department of Exercise and Nutrition Sciences, University at Buffalo, Buffalo, New York

12 ⁴U.S. Army Institute of Surgical Research, Fort Sam Houston, TX

13 Disclaimer:

14 *The opinions or assertions contained herein are the private views of the authors and are not to*
15 *be construed as official or as reflecting the views of the US Department of the Army or the US*
16 *Department of Defense.*

17 Corresponding Author

18 Blair D. Johnson

19 208A Kimball Tower

20 Buffalo, New York 14214

21 Email: blairjoh@buffalo.edu

22 Phone: 716-829-6789

23 ABSTRACT

24 We tested the hypothesis that markers of coagulation activation are greater during lower body
25 negative pressure (LBNP) than those obtained during blood loss (BL). We assessed coagulation
26 using both standard clinical tests and thrombelastography in 12 men who performed a LBNP and
27 BL protocol in a randomized order. LBNP consisted of 5-minute stages at 0, -15, -30, and -45
28 mmHg of suction. BL included 5 minutes at baseline and following three stages of 333 mL of
29 blood removal (up to 1000 mL total). Arterial blood draws were performed at baseline and after
30 the last stage of each protocol. We found that LBNP to -45mmHg is a greater central
31 hypovolemic stimulus vs. BL, therefore the coagulation markers were plotted against central
32 venous pressure (CVP) to obtain stimulus-response relationships using the linear regression line
33 slopes for both protocols. Paired t-tests were used to determine if the slopes of these regression
34 lines fell on similar trajectories for each protocol. Mean regression line slopes for coagulation
35 markers vs. CVP fell on similar trajectories during both protocols, except for TEG α° angle (-
36 0.42 ± 0.96 during LBNP vs. -2.41 ± 1.13 $^\circ/\text{mmHg}$ during BL, $p < 0.05$). During both LBNP and
37 BL coagulation was accelerated as evidenced by shortened R-times (LBNP 9.9 ± 2.4 to 6.2 ± 1.1
38 BL 8.7 ± 1.3 to 6.4 ± 0.4 min, both $p < 0.05$). Our results indicate that LBNP models the general
39 changes in coagulation markers observed during BL.

40 **Key words:** Blood Coagulation, Hemorrhage, Lower Body Negative Pressure, Blood
41 Coagulation Tests, Humans, Central Hypovolemia

42

43

44 NEW AND NOTEWORTHY

45 Our study provides noteworthy data that directly compares blood coagulation activation induced
46 by lower body negative pressure to those observed during blood loss in conscious humans.

47

48 INTRODUCTION

49 Hemorrhage is one of the leading causes of accidental death (1) and is the leading cause
50 of death on the battlefield (8, 9). Activation of the coagulation system is vital following a
51 hemorrhagic injury to reduce the risk of exsanguination. Consequently, studying the activation of
52 the coagulation system during blood loss (BL) is of utmost importance so new therapies and
53 treatment algorithms, such as fluid resuscitation, can be developed. However, using invasive
54 methods to experimentally induce BL is challenging to perform in humans.

55 Lower body negative pressure (LBNP) is a technique that is used as a non-invasive
56 surrogate to study many of the physiological responses to BL (4, 15, 18). LBNP sequesters
57 circulating blood in the lower body thereby reducing central blood volume and mimicking
58 hemodynamic responses generated during BL (4, 15, 18). However, it is unclear if markers of
59 coagulation system activation respond similarly during these protocols. Reductions in central
60 blood volume by LBNP (38) or orthostatic stress (10, 21, 36) activate the coagulation cascade,
61 therefore it is likely that central hypovolemia during BL elicits comparable changes in
62 coagulation when the degree of central hypovolemia is similar between LBNP and BL.

63 In spite of the similarities between the hemodynamic responses to LBNP and BL, these
64 protocols cause central hypovolemia in fundamentally different ways that might cause
65 differential coagulation responses. The suction applied during LBNP produces a pressure
66 gradient that pulls fluid from the intravascular compartment to the extravascular space in the
67 lower body resulting in hemoconcentration (5, 29, 34). Plasma protein concentration and blood
68 viscosity both increase, which creates a procoagulant milieu due to increased interactions
69 between coagulation factors and cellular contributors to coagulation (12, 17, 21). However, BL

has the opposite effect. The reduction in circulating blood volume causes fluid to shift from the extravascular space to the intravascular space resulting in hemodilution (7, 27, 39) and a lower blood viscosity (3). The divergent hematocrit and viscosity responses to LBNP and BL may differentially influence coagulation responses during these two protocols, despite similar hemodynamic responses.

To explore whether LBNP can be used as a model for BL in studies of coagulation activation during BL, we compared markers of coagulation activation during LBNP to those generated during BL in humans. We hypothesized that the stimulus-response relationships of central hypovolemia to coagulation responses during LBNP would be greater than those observed during BL for a given central hypovolemic stimulus due to the increases in blood viscosity and hemoconcentration during LBNP.

94 **METHODS**

95 *Subjects*

96 Twelve healthy men (age: 32 ± 2 years; height: 181.8 ± 2.0 cm; weight: 88.4 ± 2.5 kg;
97 BMI: 26.7 ± 0.5 kg/m²) participated in this study, which was approved by the Institutional
98 Review Board. Prior to participation, all subjects provided written informed consent after all
99 procedures and study risks were fully explained. Subjects were non-obese (BMI < 30), non-
100 smokers, did not take any medications and all subjects reported to be free of cardiovascular,
101 respiratory, neurologic, and metabolic disease. Following an overnight fast, subjects reported to
102 the Clinical Research Trial Unit (CRTU) of Mayo Clinic at 07:00. Upon reporting to the CRTU,
103 subjects consumed a small breakfast bar (Cliff Bar; Shelton, CT, USA; 240 kcals) and drank 250
104 mL of water. Subjects were studied in the supine position in a temperature-controlled room (20-
105 22° C).

106 *Experimental Design*

107 The study timeline is presented in Figure 1. The experimental design and selection of
108 LBNP and BL protocols have been detailed previously and the comprehensive hemodynamic and
109 circulating catecholamine responses to these protocols have been reported (18, 26). Briefly, the
110 objective of this analysis was to determine if changes in coagulation markers, obtained from our
111 previous investigations (18, 26), were similar across a broad range of CVP elicited by LBNP and
112 BL. Both protocols were performed on the same day and the order was randomized. Subjects
113 were supine for 60-90 minutes prior to initiating the first protocol (≥ 30 minutes following
114 invasive instrumentation). After the first protocol, subjects rested quietly for 45-75 minutes in
115 the supine position. A longer duration was needed after the BL protocol to allow for blood re-

infusion. Arterial blood samples were collected at baseline and at the conclusion of each protocol. During the LBNP protocol, blood samples were collected shortly before suction was terminated. The protocols were terminated if mean arterial pressure fell by 30%, systolic blood pressure dropped below 80 mmHg, or the subject began to experience symptoms of pre-syncope or syncope.

LBNP protocol

Subjects laid in an LBNP chamber sealed at the iliac crest. The LBNP protocol was based on the first 3 stages of the protocol frequently used by the U.S. Army Institute of Surgical Research (4) (Figure 1). Following a 5-minute baseline period, the protocol commenced and consisted of 5-minute stages at 15, 30, and 45 mmHg of LBNP. Subjects were instructed not to move throughout the protocol.

Blood Loss protocol

A 14-gauge catheter was inserted into an antecubital vein for blood removal during the BL protocol. Preservative/anticoagulant bags (63 mL anti-coagulant citrate phosphate dextrose solution) were positioned below the subject to facilitate blood transfer from the subject to the blood collection bags via gravity. Following a 5-minute baseline period, 3 aliquots of 333 mL of blood were removed. A 5-minute period separated each aliquot to emulate the LBNP stages. In two subjects, a blood pressure cuff was inflated around the upper arm to 40 mmHg to enhance the rate of blood removal and this cuff pressure was released prior to all measurements. As blood was collected, it was weighed to determine the volume of blood removed by multiplying the weight of the blood by 1.06 mL/g. The removed blood was kept in the study room (20-22°C) and was re-infused at a rate of 20 mL/min into the antecubital vein following the BL protocol.

138 *Hemodynamic measurements*

139 Heart rate (HR) was measured from a 3-lead ECG (Cardiacap/5, Datex-Ohmeda,
140 Louisville, CO, USA). Arterial blood pressure was measured beat-by-beat by a brachial artery
141 catheter. Central venous pressure (CVP) was measured using a peripherally inserted central
142 catheter (PICC). All lines were placed aseptically with local anesthesia by anesthesiologists. The
143 PICC was introduced through an antecubital vein and advanced to the level of the superior vena
144 cava. Placement of the PICC was estimated using external measurement of the distance from the
145 antecubital fossa to the manubrium and was verified by the identification of a typical CVP
146 waveform. The arterial catheter and the PICC were connected to pressure transducers (FloTrac,
147 Edwards Lifesciences Corp., Irvine, CA, USA) placed at the mid-axillary line). Intra-arterial
148 pressures were consistent with Riva-Rocci blood pressures.

149

150 *Hemoconcentration Measures*

151 Blood samples were analyzed by the Immunochemistry Core Laboratory of the CRTU of
152 the Mayo Clinic Center for Clinical and Translational Science. Blood samples collected in 3 mL
153 EDTA tubes were analyzed for hemoglobin (Hb), hematocrit (Hct), red blood cell count (RBC)
154 and platelet count. Total blood volume at baseline (BV_0) was estimated according to Retzlaff et
155 al.(25) using the following equation:

156
$$BV_0 = 31.9 \times \text{height (cm)} + 26.3 \times \text{weight (kg)} - 2402$$

157 Changes in blood volume and the estimated percentage change in plasma volume from
158 pre to post LBNP and from pre to post BL (%dPV) were determined using the formula by Dill

and Costill(6). Changes in hemoglobin were corrected for the amount of blood withdrawn and baseline plasma percentage was defined as 1-Hct.

Hemostatic Activity of Arterial Blood

Prothrombin Time (PT) and Activated Partial Thrombin Time (APTT). Arterial blood was drawn into 3 mL sodium citrate tubes. Samples were centrifuged for 10 minutes at 3000 x g. Platelet-poor plasma was aliquoted into tubes and stored in a freezer at -80°C until assayed. Assays were performed using a coagulation analyzer (STA-R Evolution, France) and Prothrombin time (PT) and activated partial thrombin time (APTT) were determined by standard coagulometric methods using standard reagents (PT = HemosIL RecombiPlasTin 2G; APTT = HemosIL SynthASil, Instrumentation Laboratory, Bedford, MA, USA).

Whole Blood Thromboelastography (TEG). TEG was performed on 1.5 mL of citrated whole arterial blood using a TEG 5000 device (Haemonetics Corp., Braintree, MA, USA) within four minutes of blood sampling. Samples were activated with kaolin and the analyzer produced a graphical representation of clot formation, strength, and breakdown. We recorded the following values: R, the period of time from initiation of the test to initial fibrin formation; K, time of beginning of clot formation until the amplitude of the thromboelastogram reaches 20 mm; α angle, the angle between the line in the middle of the TEG tracing and the line tangential to the developing 'body' of the TEG tracing which is reflective of the rate of fibrin polymerization; maximum amplitude (MA), expressing the maximum strength in millimeters of the final clot;

and lysis 30 (LY30) and lysis 60 (LY60) which reflect fibrinolysis and are expressed as the percent decrease in amplitude at 30 and 60 minutes, respectively, after MA.

Catecholamines

Plasma epinephrine and norepinephrine concentrations were determined from 4.5 mL of arterial blood using HPLC after prior alumina extraction (ESA Coulochem III, Dionex, Sunnyvale, CA, USA).

Data and statistical analysis

Data were collected and analyzed off-line using signal processing software (WinDaq, DATAZ Instruments, Akron, OH, USA). Hemodynamic data were analyzed and averaged over the last 2 minutes of baseline and final stages of LBNP and BL for statistical analysis. All hemodynamic signals were automatically peak-detected and manually checked. Stroke volume (SV) was determined using WinCPRS software (Absolute Aliens, Oy, Finland) by selecting the area under the arterial blood pressure curve and calculated using Modelflow (35), which simulates flow using a three-element Windkessel model. Cardiac output was calculated as the product of heart rate and stroke volume. Protocol (LBNP/BL) $\times$ time (Baseline/Protocol termination) repeated measures ANOVA was used to determine if values obtained during the LBNP protocol were similar to values during the BL protocol. If a significant main or interaction effect was obtained, Tukey's post hoc test was performed to determine where differences existed. If data were not normally distributed the Wilcoxon Signed Rank test was used. As a post hoc test, we compared the relationship between coagulation markers and hypovolemia during BL and LBNP to adjust for differences in hypovolemia. We performed this analysis by plotting the

coagulation markers against CVP to obtain stimulus-response relationships using the linear regression line slopes as we (18) and others (24) have done previously. Previous experimental investigations have found that CVP decreases early and linearly during both LBNP and BL protocols (11, 14-16, 18, 22, 24, 31). Paired t-tests were used to determine if the slopes of these regression lines fell on similar trajectories between the two protocols. Group data are presented as mean $\pm$ SE. P values are reported.

226 RESULTS

227 Of the 12 subjects, 2 subjects did not complete both protocols (both subjects completed
228 667 mL of BL and 30 mmHg of LBNP); additionally, one subject did not complete the LBNP
229 protocol (completed 30 mmHg of LBNP), and one subject did not complete the BL protocol
230 (completed 333 mL of BL). These protocols were terminated early due to pre-syncope symptoms
231 or syncope. Data obtained from the final completed stage were used for these subjects. The
232 mean time for 1000 mL of blood removal was 1402 ± 157 seconds (~ 43 mL/min). The mean
233 hemodynamic values obtained during both protocols are presented in Table 1 and are reported
234 elsewhere¹. The mean TEG coagulation values across the range of CVP during LBNP and BL
235 are displayed in Figure 2. Changes in complete blood counts are shown in Table 2. The mean
236 standard coagulation tests and the TEG lysis values at baseline and protocol termination are
237 displayed in Tables 3 and 4. The mean catecholamine concentrations are presented in Table 5.

238

239 *Effects of LBNP and BL on Hemodynamics*

240 Table 1 shows that both LBNP and BL evoked pronounced hemodynamic changes from
241 baseline to protocol termination. At baseline, CVP (LBNP 7.3 ± 0.6 BL 6.1 ± 0.6 mmHg, $p =$
242 0.024) was slightly lower during BL while SV (LBNP 83.2 ± 2.7 BL 89.5 ± 2.7 mL, $p = 0.016$),
243 and CO (LBNP 5.0 ± 0.3 BL 5.3 ± 0.3 L/min, $p = 0.045$) were slightly higher. At protocol
244 termination, CVP (LBNP -0.2 ± 0.6 BL 1.8 ± 0.8 mmHg, $p \leq 0.001$), SV (LBNP 54.1 ± 3.3 BL
245 70.5 ± 2.7 mL, $p \leq 0.001$) and CO (LBNP 4.1 ± 0.1 BL 4.7 ± 0.2 L/min, $p = 0.002$) were lower
246 during LBNP, and HR was higher (LBNP 80 ± 5.1 BL 67 ± 2.6 bpm, $p \leq 0.001$) versus BL.
247 Overall, 45 mmHg of LBNP caused greater changes in hemodynamic parameters than 1000 mL
248 of BL.

249

250 *Effects of LBNP and BL on Hemoconcentration*

251 As we expected, several markers indicated that LBNP caused hemoconcentration, while
252 BL induced hemodilution (Table 2). After LBNP there was an increase in hemoglobin ($14.2 \pm$
253 0.4 to 14.7 ± 0.4 g/dL, $p = 0.003$) and hematocrit (41 ± 0.8 to 42 ± 0.8 %, $p = 0.001$) and a
254 decrease in estimated plasma volume (59 ± 0.8 to 56 ± 0.9 %, $p \leq 0.001$) compared to baseline
255 values. BL induced a decrease in hemoglobin (14.3 ± 0.4 to 14.0 ± 0.4 g/dL, $p = 0.006$) and
256 hematocrit (41 ± 0.8 to 40 ± 0.9 %, $p = 0.006$) and an increase in estimated plasma volume ($59 \pm$
257 0.9 to 61 ± 1.1 %, $p = 0.004$) compared to baseline values. At protocol termination, hemoglobin
258 ($p \leq 0.001$) and hematocrit ($p \leq 0.001$) were lower in BL versus LBNP and estimated plasma
259 volume ($p \leq 0.001$) was greater in BL when compared to LBNP.

260 *Effects of LBNP and BL on Standard Laboratory Coagulation Tests*

261 Mean PT (12.2 ± 0.2 to 12.0 ± 0.1 s, Wilcoxon signed rank post hoc test $p = 0.026$) and
262 APTT (32.2 ± 0.7 to 31.0 ± 0.8 s, Wilcoxon signed ranked post hoc test $p = 0.047$) were quicker
263 after LBNP vs. baseline (Table 3).

264 *Effects of LBNP and BL on TEG values*

265 At protocol termination, R times were quicker versus baseline for both LBNP and BL
266 protocols (LBNP 9.9 ± 2.4 to 6.2 ± 1.1 BL 8.7 ± 1.3 to 6.4 ± 0.4 min, Wilcoxon signed rank post
267 hoc test $p = 0.037$ and $p = 0.039$, Figure 2) and these relative changes were not different from
268 each other. Regression line slopes produced from the relationship between TEG measures and
269 CVP fell on similar trajectories during LBNP and BL, except for the slope of α angle vs. CVP ($-$
270 0.42 ± 0.96 during LBNP vs. -2.41 ± 1.13 °/mmHg during BL, $p = 0.046$).

Effects of LBNP and BL on Catecholamine Levels

Epinephrine (LBNP 53 ± 7 to 144 ± 30 BL 49 ± 7 to 103 ± 19 pg/mL, $p \leq 0.001$ and $p = 0.002$) and norepinephrine (LBNP 148 ± 20 to 354 ± 44 BL 155 ± 22 to 211 ± 29 pg/mL, $p \leq 0.001$ and $p = 0.043$) concentrations were both elevated at protocol termination in both LBNP and BL protocols (Table 5). Norepinephrine levels were higher during LBNP versus BL at protocol termination ($p = 0.003$).

294 DISCUSSION

295 The general results of this study indicate that BL and LBNP induce similar coagulation
296 response trajectories across a wide range of CVP. Only the slope of TEG α angle was statistically
297 different between protocols.

298 Central hypovolemia, induced by either BL or LBNP, alters blood coagulation status,
299 which is evidenced by a reduction in R-time obtained from TEG. The greater degree of
300 hypovolemia induced by LBNP in this study also demonstrated coagulation activation by
301 reducing PT and APTT. This is in line with the reported activation of coagulation during LBNP
302 (38) and other orthostatic challenges (10, 21, 36). Because direct vascular damage due to arterial
303 and venous catheter placement was likely minimal in our study, it is probable that other factors
304 contributed to the coagulation response. The increase in circulating catecholamines in both
305 LBNP and BL protocols may have contributed to the hypercoagulable milieu. Intravenous
306 administration of epinephrine has been shown to accelerate blood coagulation (2, 33).
307 Additionally, hemostatically active von Willebrand factor, clotting factor VIII, and tissue-type
308 plasminogen activator are released from endothelial cells (32) or the spleen (19) into the
309 circulation via stimulation of endothelial β_2 -adrenoreceptors (32). This mechanism of
310 epinephrine-induced release of coagulation factors has also been implicated during other
311 orthostatic challenges (10, 36). Splenic release of platelets has also been found following
312 adrenergic stimulation (19). Therefore, it is likely that sympathoexcitation and release of
313 epinephrine during BL and LBNP contribute to the coagulation response. We found significant
314 increases in epinephrine after both LBNP and BL, suggesting that this hormone plays an
315 important role in activating the coagulation system.

We observed a very small decrease in PT and APTT times during LBNP. Other investigators have also found a decrease in PT time during orthostatic challenges (21). Our observation is likely due in part to a reduction in plasma volume by ~4% during LBNP. However, plasma volume increased by ~3% during BL. This might explain the small increase in PT and almost no change in APTT from baseline to protocol termination during BL (Table 3). Because of the divergent effects of LBNP and BL on plasma volume, it appears as though plasma markers of coagulation might not be appropriate to assess coagulation during LBNP and experimental BL.

Data obtained from TEG analysis of whole blood might be a better method to assess changes in coagulation than plasma markers due to the changes in plasma volume during LBNP and BL that we observed. TEG analysis has also been shown to be a better indicator of hemostasis than PT (20, 23). Recently, Zaar et al. demonstrated a reduction in time to fibrin formation after LBNP to presyncope demonstrated by shortened R-time (37). However, PT and APTT were unaffected. TEG R-times were shortened during both LBNP and BL protocols in our study. As little as ~300 mL of blood loss during surgery (30) and 480 mL of blood removal (28) have both been shown to reduce R-time and increase α angle, or the rate of clot formation. In another study by Zaar and colleagues (39), a graded reduction in R-time from 450 mL to 900 mL of blood removal as well as an increase in α angle was observed, but only following 900 mL of blood loss. However, we did not observe a large increase in the α angle following 1000 mL of BL or following LBNP. This discrepancy might have occurred due to differences in the rate of blood removal (~43 mL/min in our study vs. ~30 mL/min). Additionally, we removed blood into 3 separate 333 mL aliquots whereas Zaar et al. (39) used two 450 mL aliquots to protocol completion when compared to our protocol. Although α angle was not statistically

distinguishable from baseline to protocol termination in both LBNP and BL protocols, the stimulus-response trajectory of CVP- α angle was steeper during BL when compared to LBNP. This discrepancy is primarily due to the differences in CVP achieved at the end of each protocol, as α angle was not different between protocols (Figure 2). Contrary to a recent study that found increased LY 60 (37) after LBNP, we did not find any differences in TEG measured fibrinolysis (Table 4). This may have been the result of a large interindividual variability in TEG lysis values.

The more robust change in whole blood TEG-R time after both LBNP and BL compared to the very subtle change in platelet-poor plasma based assays PT and APTT after LBNP indicates that platelets contribute significantly to coagulation acceleration during central hypovolemia. Consistent with this idea, platelet activation, demonstrated by increased exposure of active glycoprotein 2b/3a, has been shown after LBNP (37). We observed an increase in platelet count after both LBNP and BL. This increase occurred despite hemodilution during BL, which suggests that platelets were released from the spleen.

Methodological considerations

Several methodological considerations pertain to our study. First, we collected blood only at baseline and at the termination of each protocol. Collecting multiple samples throughout both protocols would have allowed us to identify if a graded hypercoagulable state exists throughout a range of central hypovolemia within each subject (30, 39). Second, we did not match CVP between protocols. The goal of our study was to determine if changes in coagulation markers were similar across a broad range of central hypovolemia elicited by LBNP and BL. However, LBNP caused a greater reduction in central blood volume indicated by lower CVP, stroke

volume, and cardiac output values as well as higher heart rate and norepinephrine values when compared to BL. If we had matched CVP between the two protocols, we might have been able to provide additional information about how comparable the coagulation responses are throughout LBNP and BL. Third, we have no direct recordings of sympathetic nerve activity; this would have provided additional information regarding the contribution of the sympathetic nervous system in the activation of blood coagulation during central hypovolemia. Fourth, the protocol times were not matched. The time between the first and second blood draw was 20 minutes during the LBNP protocol and approximately 45 minutes during the BL protocol. This could introduce a difficulty in interpreting the results if there were a time effect on coagulation in the subjects due to prolonged rest in a supine position. However when we compared the baseline TEG R values of the first protocol that subjects underwent versus the baseline values of the second protocol, the R times were statistically indistinguishable (paired t-test $p = 0.219$), suggesting that supine position did not contribute significantly to observed changes in coagulation status. Fourth, subjects were randomized to LBNP and BL and underwent both protocols on the same day. Our assumption was that baseline cardiovascular and coagulation variables would not be different, regardless of protocol randomization order. We tested our assumption and performed paired t-tests on LBNP and BL Baseline hemodynamic and coagulation variables. We found that subjects who performed LBNP first had slightly lower CVP (~ 1.5 mmHg) and slightly higher SV (~ 10 mL) at baseline BL ($p = 0.025$ and $p = 0.032$ respectively). Perhaps this had a lasting effect on the greater increase in catecholamines during LBNP on cardiac contractility. This small order effect might explain the slight differences in these hemodynamic parameters we found between baselines. Finally, the method of Dill and Costill (6) was used for determinations of relative plasma volume changes. This requires that the

distribution of red cells throughout the vascular bed is similar between LBNP and BL (13).
However, the distribution of red blood cells throughout the vasculature might have been different
between protocols leading to underestimation of changes in plasma volume.

CONCLUSIONS

Our results indicate that 45 mmHg of LBNP elicited slightly greater increases in plasma
measures of coagulation (PT and APTT) than 1000 mL of BL. When coagulation activation was
measured in whole blood by TEG, we saw a robust change in R-time during both protocols. This
indicates that cellular contributions to the coagulation response during central hypovolemia are
important. The stimulus-response trajectories for most markers of coagulation versus CVP were
similar between the two protocols, which indicates that acceleration of the coagulation system is
comparable between LBNP and BL within the range of central hypovolemia that we tested.
Therefore, LBNP appears to be a useful surrogate to study the coagulation system during BL.

ACKNOWLEDGEMENTS

We thank the subjects who participated in this study. We also thank Christopher P. Johnson,
Margaret McGill-Zimny, Shelly K. Roberts, David Warren, and Sarah C. Wolhart for their
assistance.

GRANTS

Support for this study was provided by U.S. Army MPMC Combat Casualty Care Research
Program Grant W81XWH-11-1-0823, American Heart Association Midwest Affiliate Grant
13POST-14380027 to B.D.J., and by Dutch Heart Foundation E. Dekker Stipend 2012SB013 to
N.V.H.

Table 1. Changes in hemodynamic variables with LBNP and BL.

		Baseline	Termination
CVP (mmHg)	LBNP	7.3 ± 0.6	-0.2 ± 0.6 [*]
	BL	6.1 ± 0.6 [†]	1.8 ± 0.8 ^{*†}
HR (bpm)	LBNP	60 ± 2.5	80 ± 5.1 [*]
	BL	60 ± 2.8	67 ± 2.6 ^{*†}
MAP (mmHg)	LBNP	93.5 ± 2.3	84.5 ± 4.7 [*]
	BL	91.8 ± 1.9	87.0 ± 2.7
SV (mL)	LBNP	83.2 ± 2.7	54.1 ± 3.3 [*]
	BL	89.5 ± 2.7 [†]	70.5 ± 2.7 ^{*†}
CO (L/min)	LBNP	5.0 ± 0.3	4.1 ± 0.1 [*]
	BL	5.3 ± 0.3 [†]	4.7 ± 0.2 ^{*†}

LBNP = lower body negative pressure; BL = blood loss.

Values are means ± standard error, n = 12.

^{*}Different from Baseline (P < 0.05); [†]Different vs. LBNP

406

407

Table 2. Effects of LBNP and BL on complete blood counts.

		Baseline	Termination
Hgb (g/dL)	LBNP	14.2 ± 0.4	14.7 ± 0.4 [*]
	BL	14.3 ± 0.4	14.0 ± 0.4 ^{*†}
Hct (%)	LBNP	41 ± 0.8	42 ± 0.8 [*]
	BL	41 ± 0.8	40 ± 0.9 ^{*†}
RBC (*10 ¹² /L)	LBNP	4.8 ± 0.1	5.0 ± 0.1 [*]
	BL	4.8 ± 0.1	4.7 ± 0.1 ^{*†}
Plasma volume (%)	LBNP	59 ± 0.8	56 ± 0.9 [*]
	BL	59 ± 0.9	61 ± 1.1 ^{*†}
Platelet count (*10 ⁹ /L)	LBNP	194 ± 7	212 ± 10 [*]
	BL	186 ± 9	200 ± 11 [*]

LBNP = lower body negative pressure; BL = blood loss.

Values are means ± standard error, n = 12.

^{*}Different from Baseline (P < 0.05); [†]Different from lower body negative pressure (P < 0.05).

408

409

410

411

412

413

414

415

416

417

418

419

420

Table 3. Effects of LBNP and BL on standard coagulation tests.

		Baseline	Termination
PT (s)	LBNP	12.2 ± 0.2	12.0 ± 0.1*
	BL	12.1 ± 0.2	12.2 ± 0.3
APTT (s)	LBNP	32.2 ± 0.7	31.0 ± 0.8*
	BL	32.6 ± 0.9	32.4 ± 0.9

LBNP = lower body negative pressure; BL = blood loss.

Values are means ± standard error, n = 12.

*Different from Baseline (P < 0.05)

421

422

423

424

425

426

427

428

429

430

431

432

433

Table 4. Effects of LBNP and BL on clot lysis measures.

		Baseline	Termination
LY30 (%)	LBNP	1.6 ± 0.4	3.6 ± 1.7
	BL	2.3 ± 1.1	3.1 ± 1.6
LY60 (%)	LBNP	5.6 ± 1.1	7.5 ± 2.5
	BL	6.1 ± 1.9	7.4 ± 2.5

LBNP = lower body negative pressure; BL = blood loss.
Values are means ± standard error, n = 12.

434

435

436

437

438

439

440

441

442

443

444

445

Table 5. Effects of LBNP and BL on catecholamine levels.

		Baseline	Termination
Norephineprine (pg/mL)			
	LBNP	148 ± 20	354 ± 44 [*]
	BL	155 ± 22	211 ± 29 ^{*†}
Epinephrine (pg/mL)			
	LBNP	53 ± 7	144 ± 30 [*]
	BL	49 ± 7	103 ± 19 [*]

LBNP = lower body negative pressure; BL = blood loss.

Values are means ± standard error, n = 12.

^{*}Different from Baseline (P < 0.05); [†]Different from lower body negative pressure (P < 0.05).

446

447

448

449

450

451

452

453

454

455

456

Figure 1. Timeline of the lower body negative pressure and blood loss protocols. The order of the protocols was randomized. When the lower body negative pressure protocol was performed first, 45 minutes of quiet rest was given between protocols to ensure hemodynamic variables returned to baseline. To allow for the reinfusion of removed blood, 75 minutes of quiet resting was given to allow for hemodynamic variables to return to baseline between protocols when blood loss occurred first. Blood was drawn at baseline and during the last stage of each protocol.

Figure 2. Mean $\pm$ SEM TEG values (A) R, (B) K, (C) alpha angle, and (D) MA plotted against mean CVP $\pm$ SEM at baseline and immediately after protocol termination during the LBNP and BL protocols. All response trajectories were similar between LBNP and BL protocols with the exception of alpha angle, which was steeper during BL versus LBNP.

*Different versus BL; $p = 0.046$.

480 REFERENCES

- 481 1. **Boulanger L, Joshi AV, Tortella BJ, Menzin J, Caloyeras JP, and Russell MW.**
482 Excess mortality, length of stay, and costs associated with serious hemorrhage among trauma
483 patients: findings from the National Trauma Data Bank. *Am Surg* 73: 1269-1274, 2007.
- 484 2. **Cannon WB and Gray H.** Factors affecting the coagulation time of blood. 2. The
485 hastening or retarding of coagulation by adrenalin injections. . *Am J Physiol* 34: 232-242, 1914.
- 486 3. **Chatpun S and Cabrales P.** Effects on cardiac function of a novel low viscosity plasma
487 expander based on polyethylene glycol conjugated albumin. *Minerva anesthesiologica* 77: 704-
488 714, 2011.
- 489 4. **Cooke WH, Ryan KL, and Convertino VA.** Lower body negative pressure as a model
490 to study progression to acute hemorrhagic shock in humans. *Journal of applied physiology*
491 (*Bethesda, Md : 1985*) 96: 1249-1261, 2004.
- 492 5. **Cvirn G, Schlagenhaut A, Leschnik B, Koestenberger M, Roessler A, Jantscher A,**
493 **Vrecko K, Juergens G, Hinghofer-Szalkay H, and Goswami N.** Coagulation changes during
494 presyncope and recovery. *PloS one* 7: e42221, 2012.
- 495 6. **Dill DB and Costill DL.** Calculation of percentage changes in volumes of blood, plasma,
496 and red cells in dehydration. *J Appl Physiol* 37: 247-248, 1974.
- 497 7. **Drobin D and Hahn RG.** Volume kinetics of Ringer's solution in hypovolemic
498 volunteers. *Anesthesiology* 90: 81-91, 1999.
- 499 8. **Eastridge BJ, Hardin M, Cantrell J, Oetjen-Gerdes L, Zubko T, Mallak C, Wade**
500 **CE, Simmons J, Mace J, Mabry R, Bolenbaucher R, and Blackbourne LH.** Died of wounds
501 on the battlefield: causation and implications for improving combat casualty care. *J Trauma* 71:
502 S4-8, 2011.

- 503 9. **Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, Mallett O, Zubko**
504 **T, Oetjen-Gerdes L, Rasmussen TE, Butler FK, Kotwal RS, Holcomb JB, Wade C,**
505 **Champion H, Lawnick M, Moores L, and Blackbourne LH.** Death on the battlefield (2001-
506 2011): implications for the future of combat casualty care. *J Trauma Acute Care Surg* 73: S431-
507 437, 2012.
- 508 10. **Feng DL, Murillo J, Jadhav P, McKenna C, Gebara OC, Lipinska I, Muller JE, and**
509 **Tofler GH.** Upright posture and maximal exercise increase platelet aggregability and
510 prostacyclin production in healthy male subjects. *British journal of sports medicine* 33: 401-404,
511 1999.
- 512 11. **Gauer OH, Henry JP, and Sieker HO.** Changes in central venous pressure after
513 moderate hemorrhage and transfusion in man. *Circ Res* 4: 79-84, 1956.
- 514 12. **Hagan RD, Diaz FJ, and Horvath SM.** Plasma volume changes with movement to
515 supine and standing positions. *Journal of applied physiology: respiratory, environmental and*
516 *exercise physiology* 45: 414-417, 1978.
- 517 13. **Harrison MH, Graveney MJ, and Cochrane L.** Some sources of error in the
518 calculation of relative change in plasma volume. *Europ J Appl Physiol* 50: 13-21, 1982.
- 519 14. **Henry JP, Gauer OH, and Sieker HO.** The effect of moderate changes in blood volume
520 on left and right atrial pressures. *Circ Res* 4: 91-94, 1956.
- 521 15. **Hinojosa-Laborde C, Shade RE, Muniz GW, Bauer C, Goei KA, Pidcoke HF,**
522 **Chung KK, Cap AP, and Convertino VA.** Validation of lower body negative pressure as an
523 experimental model of hemorrhage. *J Appl Physiol (1985)* 116: 406-415, 2014.

- 524 16. **Hirsch AT, Levenson DJ, Cutler SS, Dzau VJ, and Creager MA.** Regional vascular
525 responses to prolonged lower body negative pressure in normal subjects. *Am J Physiol* 257:
526 H219-225, 1989.
- 527 17. **Jen CJ and McIntire LV.** Characteristics of shear-induced aggregation in whole blood.
528 *The Journal of laboratory and clinical medicine* 103: 115-124, 1984.
- 529 18. **Johnson BD, van Helmond N, Curry TB, van Buskirk CM, Convertino VA, and**
530 **Joyner MJ.** Reductions in central venous pressure by lower body negative pressure or blood loss
531 elicit similar hemodynamic responses. *J Appl Physiol (1985)* 117: 131-141, 2014.
- 532 19. **Libre EP, Cowan DH, Watkins SP, Jr., and Shulman NR.** Relationships between
533 spleen, platelets and factor 8 levels. *Blood* 31: 358-368, 1968.
- 534 20. **Martini WZ, Cortez DS, Dubick MA, Park MS, and Holcomb JB.**
535 Thrombelastography is better than PT, aPTT, and activated clotting time in detecting clinically
536 relevant clotting abnormalities after hypothermia, hemorrhagic shock and resuscitation in pigs.
537 *The Journal of trauma* 65: 535-543, 2008.
- 538 21. **Masoud M, Sarig G, Brenner B, and Jacob G.** Orthostatic hypercoagulability: a novel
539 physiological mechanism to activate the coagulation system. *Hypertension* 51: 1545-1551, 2008.
- 540 22. **Norsk P, Bonde-Petersen F, and Warberg J.** Influence of central venous pressure
541 change on plasma vasopressin in humans. *J Appl Physiol (1985)* 61: 1352-1357, 1986.
- 542 23. **Park MS, Martini WZ, Dubick MA, Salinas J, Butenas S, Kheirabadi BS, Pusateri**
543 **AE, Vos JA, Guymon CH, Wolf SE, Mann KG, and Holcomb JB.** Thromboelastography as a
544 better indicator of hypercoagulable state after injury than prothrombin time or activated partial
545 thromboplastin time. *The Journal of trauma* 67: 266-275; discussion 275-266, 2009.

- 546 24. **Rea RF, Hamdan M, Clary MP, Randels MJ, Dayton PJ, and Strauss RG.**
547 Comparison of muscle sympathetic responses to hemorrhage and lower body negative pressure
548 in humans. *J Appl Physiol* (1985) 70: 1401-1405, 1991.
- 549 25. **Retzlaff JA, Tauxe WN, Kiely JM, and Stroebel CF.** Erythrocyte volume, plasma
550 volume, and lean body mass in adult men and women. *Blood* 33: 649-661, 1969.
- 551 26. **Rickards CA, Johnson BD, Harvey RE, Convertino VA, Joyner MJ, and Barnes JN.**
552 Cerebral blood velocity regulation during progressive blood loss compared to lower body
553 negative pressure in humans. *J Appl Physiol* (1985): jap 00127 02015, 2015.
- 554 27. **Riddez L, Johnson L, and Hahn RG.** Central and regional hemodynamics during
555 crystalloid fluid therapy after uncontrolled intra-abdominal bleeding. *The Journal of trauma* 44:
556 433-439, 1998.
- 557 28. **Ruttmann TG, Roche AM, Gasson J, and James MF.** The effects of a one unit blood
558 donation on auto-haemodilution and coagulation. *Anaesthesia and intensive care* 31: 40-43,
559 2003.
- 560 29. **Sander-Jensen K, Mehlsen J, Stadeager C, Christensen NJ, Fahrenkrug J, Schwartz**
561 **TW, Warberg J, and Bie P.** Increase in vagal activity during hypotensive lower-body negative
562 pressure in humans. *Am J Physiol* 255: R149-156, 1988.
- 563 30. **Tuman KJ, Spiess BD, McCarthy RJ, and Ivankovich AD.** Effects of progressive
564 blood loss on coagulation as measured by thrombelastography. *Anesthesia and analgesia* 66:
565 856-863, 1987.
- 566 31. **van Hoeyweghen R, Hanson J, Stewart MJ, Dethune L, Davies I, Little RA, Horan**
567 **MA, and Kirkman E.** Cardiovascular response to graded lower body negative pressure in young
568 and elderly man. *Exp Physiol* 86: 427-435, 2001.

- 569 32. **von Kanel R and Dimsdale JE.** Effects of sympathetic activation by adrenergic
570 infusions on hemostasis in vivo. *European journal of haematology* 65: 357-369, 2000.
- 571 33. **Vosburgh CH and Richards AN.** An experimental study of the sugar content and
572 extravascular coagulation of the blood after administration of adrenalin. *American Journal of*
573 *Physiology* 9: 35-51, 1903.
- 574 34. **Ward KR, Tiba MH, Ryan KL, Filho IP, Rickards CA, Witten T, Soller BR,**
575 **Ludwig DA, and Convertino VA.** Oxygen transport characterization of a human model of
576 progressive hemorrhage. *Resuscitation* 81: 987-993, 2010.
- 577 35. **Wesseling KH, Jansen JR, Settels JJ, and Schreuder JJ.** Computation of aortic flow
578 from pressure in humans using a nonlinear, three-element model. *Journal of applied physiology*
579 *(Bethesda, Md : 1985)* 74: 2566-2573, 1993.
- 580 36. **Winther K, Hillegass W, Tofler GH, Jimenez A, Brezinski DA, Schafer AI, Loscalzo**
581 **J, Williams GH, and Muller JE.** Effects on platelet aggregation and fibrinolytic activity during
582 upright posture and exercise in healthy men. *The American journal of cardiology* 70: 1051-1055,
583 1992.
- 584 37. **Zaar M, Fedyk CG, Pidcock HF, Scherer MR, Ryan KL, Rickards CA, Hinojosa-**
585 **Laborde C, Convertino VA, and Cap AP.** Platelet activation after presyncope by lower body
586 negative pressure in humans. *PLoS One* 9: e116174, 2014.
- 587 38. **Zaar M, Johansson PI, Nielsen LB, Crandall CG, Shibasaki M, Hilsted L, and**
588 **Secher NH.** Early activation of the coagulation system during lower body negative pressure.
589 *Clinical physiology and functional imaging* 29: 427-430, 2009.

590 39. **Zaar M, Morkeberg J, Pott FC, Johansson PI, and Secher NH.** Coagulation
591 competence and fluid recruitment after moderate blood loss in young men. *Blood Coagul*
592 *Fibrinolysis* 25: 592-596, 2014.

Figure 1.





Figure 2.



Reductions in Central Venous Pressure by Lower Body Negative Pressure or Blood Loss Elicit Similar Hemodynamic Responses

Blair D. Johnson¹, Noud van Helmond^{1,2}, Timothy B. Curry¹, Camille M. van Buskirk³, Victor A. Convertino⁴, & Michael J. Joyner¹

¹Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota, USA

²Department of Physiology, Radboud University Nijmegen Medical Centre, Netherlands

³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

⁴US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA

Running Head: Hemodynamic responses during LBNP and blood loss

Correspondence

Blair D. Johnson

200 First Street SW

Rochester, MN 55909

Phone: 507-255-5880

Fax: 507-255-7300

Email: johnson.blair@mayo.edu

ABSTRACT

The purpose of this study was to compare hemodynamic and blood analyte responses to reduced central venous pressure (CVP) and pulse pressure (PP) elicited during graded LBNP to those observed during graded BL in conscious humans. We hypothesized that the stimulus-response relationships of CVP and PP to hemodynamic responses during LBNP would mimic those observed during BL. We assessed CVP, PP, heart rate, mean arterial pressure (MAP), and other hemodynamic markers in 12 men during LBNP and BL. Blood samples were obtained for analysis of catecholamines, hematocrit, hemoglobin, arginine vasopressin, and blood gases. LBNP consisted of 5-minute stages at 0, 15, 30, and 45 mmHg of suction. BL consisted of 5 minutes at baseline and following three stages of 333 mL of hemorrhage (1000 mL total). Individual r^2 values and linear regression slopes were calculated to determine if the stimulus (CVP and PP) - hemodynamic response trajectories were similar between protocols. The CVP-MAP trajectory was the only CVP-response slope that was statistically different during LBNP when compared to BL (0.93 ± 0.27 vs. 0.13 ± 0.26 ; $P = 0.037$). The PP-heart rate trajectory was the only PP-response slope that was statistically different during LBNP when compared to BL (-1.85 ± 0.45 vs. -0.46 ± 0.27 ; $P = 0.024$). Norepinephrine, hematocrit, and hemoglobin were all lower at termination in the BL protocol when compared to LBNP ($P < 0.05$). Consistent with our hypothesis, LBNP mimics the hemodynamic stimulus-response trajectories observed during BL across a significant range of CVP in humans.

Key Words: hemorrhage, central hypovolemia, heart rate, blood pressure, stroke volume

INTRODUCTION

Hemorrhage is one of the main causes of death associated with civilian trauma (16, 33, 35) and it is the leading cause of potentially survivable death on the battlefield (3, 14). Therefore, identifying physiological changes in response to blood loss (BL) is important because it can promote timely assessment of patient status and appropriate triage. Clinical studies of BL are difficult due to the heterogeneity of patients, injuries, volume of blood lost, and resuscitation efforts. Standardized laboratory studies where graded hypovolemia is induced via BL or dehydration provide a standardized way of measuring the effects of hypovolemia; however the removal of an adequate volume of blood to mimic clinically relevant hemorrhage in conscious humans in a laboratory is invasive and may not be practical. Therefore, lower body negative pressure (LBNP) is frequently used to simulate BL in conscious humans. The application of LBNP results in a central volume shift to the lower body which creates central hemodynamic conditions that are thought to mimic those obtained during actual BL (12). Recent evidence indicates that LBNP is a valid surrogate to simulate hemodynamic responses to BL in anesthetized baboons (23). Data obtained from human experiments also suggest that LBNP creates a hemodynamic environment that is similar to BL (20, 30, 36). In this context, it has been proposed, based on a review of LBNP and BL studies, that LBNP creates similar compensatory and hemodynamic responses as BL (12). However, a direct comparison of physiological responses during LBNP and BL have only been conducted in two previous studies, both of which involved only mildly reduced blood volume of 450 ml (20, 30). Notably, these studies did not compare hemodynamic responses throughout progressive reductions in circulating blood volume to responses obtained during graded LBNP.

Reductions in central blood volume not only cause changes in hemodynamics but blood analyte responses as well. Central hypovolemia generated by LBNP or BL is a strong activator

of the sympathetic nervous system and increases circulating catecholamines (11, 13, 15, 24, 28). Additionally, arterial and atrial mechanical stretch receptors sense the decrease in blood pressure during acute reductions in central blood volume and initiate the release of volume-regulating hormones, such as arginine vasopressin (1, 2, 11, 18, 24, 37). Therefore, it is plausible that blood analyte responses to LBNP are comparable to the blood analyte responses observed during BL. However, similar to the lack of a comparison of hemodynamic adjustments between LBNP and BL, a direct comparison of blood analyte responses to LBNP and BL has not been fully elucidated.

Despite the idea that LBNP mimics BL, a direct comparison of multiple hemodynamic and blood analyte responses to reductions in central venous pressure (CVP) and pulse pressure obtained by graded LBNP and graded BL has not been performed in conscious humans. The purpose of this study was to compare hemodynamic responses elicited during a bout of graded LBNP to those observed during graded BL in conscious humans. We hypothesized that hemodynamic responses to graded LBNP (0, 15, 30, & 45 mmHg of LBNP) would mimic hemodynamic responses observed during graded BL (0, 333, 667, 1000 ml of BL) across a wide range of CVP and pulse pressure, and these responses would be strongly correlated between the two protocols. Additionally, we hypothesized that the blood analyte responses to LBNP and BL would be similar.

METHODS

Subjects. Twelve healthy men (age: 32 ± 2 years; height: 181.8 ± 2.0 cm; weight: 88.4 ± 2.5 kg; BMI: 26.7 ± 0.5 kg/m²) were recruited to participate in this study. All subjects reported to be free of any cardiovascular, respiratory, neurologic, or metabolic disease. Subjects were required to be non-obese (BMI < 30), non-smokers, and not taking any medications. Subjects reported to the Clinical Research Unit at Mayo Clinic at 0700 following an overnight fast. At this time, subjects consumed a small breakfast bar (Cliff Bar; Shelton, CT, USA; 240 kcals) and drank 250 ml of water. Subjects were studied in the supine position in a temperature controlled room (20-22° C). Prior to the study day, all subjects provided written informed consent after all procedures and risks of the study were fully explained and the study was approved by the Institutional Review Board. To ensure subject safety, a board-certified anesthesiologist was present throughout the study day and a member of the Mayo Clinic autologous transfusion team was in attendance during the BL protocol.

Experimental Design. Subjects underwent a LBNP and a BL protocol on the same day in a randomized order. The goal of the experimental design was to create a wide range of CVP in both protocols. Based on recommendations for equating LBNP levels to BL (12), we selected the initial stages of the U.S. Army Institute for Surgical Research LBNP protocol and stepwise reductions in blood volume that would closely mirror CVP at each LBNP stage and allow hemodynamic conditions to stabilize. The order of the protocols was randomized; therefore we were unable to match CVP values between LBNP and BL due to subject safety. Prior to the first perturbation, subjects were supine for 60-90 minutes (at least 30 minutes following invasive instrumentation). Subjects rested quietly in the supine position for 45-75 minutes following the first protocol. A longer duration of rest was required after the BL protocol to allow for the re-

infusion of blood prior to the LBNP protocol. Arterial blood samples were obtained at baseline and at the termination of each protocol to measure circulating catecholamines, hematocrit, hemoglobin, blood gases, bicarbonate, and circulating arginine vasopressin. The protocols were terminated early if 1) mean arterial pressure fell by 30%, 2) systolic blood pressure dropped below 80 mmHg, or 3) the subject began to experience symptoms of pre-syncope or syncope. Figure 1 illustrates the study timeline.

Measurements and Procedures.

Heart rate and arterial oxygen saturation. A 3-lead EKG was used to continuously record heart rate and arterial oxygen saturation was obtained using a finger pulse oximeter (CardiCap/5, Datex-Ohmeda, Louisville, CO, USA). The EKG and pulse oximeter tracings were interfaced with a personal computer for continuous measurements.

Central venous pressure. A 16-gauge peripherally inserted central catheter was introduced into an antecubital vein under local anesthesia (2% lidocaine) using aseptic techniques and advanced until an appropriate CVP waveform was obtained. This catheter was connected to a high-resolution transducer (FloTrac, Edwards Lifesciences Corp., Irvine, CA, USA) positioned at heart level and interfaced with a personal computer for continuous measurement of central venous pressure.

Blood removal. A second 14-gauge catheter was placed in an antecubital vein to facilitate blood removal for the BL protocol. The catheter was placed under local anesthesia (2% lidocaine) using aseptic techniques. Preservative/anticoagulant bags (63 ml anti-coagulant citrate phosphate dextrose solution) were placed below the subject to allow blood to transfer from the subject to the blood collection bags via gravity. In two subjects, a blood pressure cuff was inflated around the upper arm to 40 mmHg to enhance the rate of blood removal and this

cuff pressure was released during all measurements. As blood was being collected, it was weighed to determine the volume of blood removed by multiplying the weight of the blood by 1.06 ml/g. The removed blood was kept in the study room (20-22°C) and the temperature of the blood was allowed fluctuate. At the end of the BL protocol, blood was re-infused at a rate of 20 ml/min into the antecubital vein.

Intra-arterial blood pressure, stroke volume, and cardiac output. A 20-gauge, 5 cm catheter was placed into a brachial artery under local anesthesia (2% lidocaine) using aseptic techniques and ultrasound guidance. The catheter was attached to a high-resolution transducer (FloTrac, Edwards Lifesciences Corp., Irvine, CA, USA) positioned, at heart level and interfaced with a personal computer to obtain continuous beat by beat arterial pressure waveforms. Pulse pressure was calculated as the difference between systolic and diastolic blood pressure. Model flow analysis software (WinCPRS, Absolute Aliens Oy, Turku, Finland) was used to calculate beat by beat stroke volume and cardiac output (38). Total peripheral resistance was calculated as mean arterial pressure divided by cardiac output.

Blood sampling and oxygen delivery. Arterial blood samples were collected at baseline and at the termination of each protocol for the measurement of the partial pressure of oxygen and carbon dioxide, pH, bicarbonate, hematocrit, hemoglobin, catecholamines, and arginine vasopressin. Blood samples were analyzed by the Immunochemistry Core Laboratory of the Clinical Research Unit of the Mayo Clinic CTSA. Oxygen delivery was calculated as: $[1.39 \times \text{hemoglobin concentration} \times \text{arterial oxygen saturation} + (0.003 \times \text{partial pressure of oxygen})] \times \text{cardiac output}$.

LBNP protocol. Subjects laid in an airtight LBNP chamber sealed at the iliac crest. The LBNP protocol was based on the first 3 stages of the protocol commonly used by the U.S. Army

Institute for Surgical Research (5, 7, 9, 22, 31, 32). The protocol consisted of a 5 minute baseline period followed by 5 minutes at 15, 30, and 45 mmHg of suction. Subjects were not allowed to cross their legs and were instructed to refrain from contracting any muscles in the lower body throughout the protocol.

BL protocol. Following a 5 minute baseline period, 3 aliquots of 333 ml of blood were removed via gravity from an antecubital vein. A 5 minute period separated each aliquot to emulate the three stages of LBNP. The removed blood was stored in standard preservative/anticoagulant bags and was periodically agitated to prevent clotting. Subjects were instructed not to cross their legs or contract any muscles in their lower body throughout the protocol.

Data and Statistical Analysis.

Data were collected and variables were analyzed off-line using signal processing software (WinDaq, DATAZ Instruments, Akron, OH, USA). Data were analyzed and averaged over the last 2 minutes of each stage for statistical analysis. To explore the relationship between BL and LBNP, individual subject r^2 values and linear regression line slopes were calculated for each variable for both protocols. Paired t-tests were used to determine if the r^2 values and slopes of the regression lines of the hemodynamic variables fell on similar trajectories throughout a range of CVP and pulse pressure during each protocol. If data were not normally distributed, the Wilcoxon Signed Rank test was used. The amalgamated r^2 value and linear regression line slopes were also calculated using linear regression analysis using group mean values obtained at each stage versus the group mean CVP and pulse pressure obtained during each stage of both protocols. Protocol $\times$ stage (2×4) repeated measures ANOVA was used to determine if values obtained during the LBNP protocol were similar to the corresponding stages

of the BL protocol. If a significant main or interaction effect was obtained, Tukey's post hoc analysis was performed to determine where differences existed. Group data are presented as mean $\pm$ SE. The alpha level was set at 0.05.

RESULTS

Of the 12 subjects who volunteered to participate in this study, 2 subjects did not complete both protocols (both subjects completed 667 ml of BL and 30 mmHg of LBNP); additionally, one subject did not complete the LBNP protocol (completed 30 mmHg of LBNP), and one subject did not complete the BL protocol (completed 333 ml of BL). These protocols were terminated early due to pre-syncope symptoms or syncope. Data obtained from subjects who did not complete 667 ml of BL or 30 mmHg of LBNP were excluded from regression analyses. A sample size of 8 subjects (age: 32 ± 3 years; height: 185.3 ± 1.8 cm; weight: 91.3 ± 3.4 kg; BMI: 26.6 ± 0.8 kg/m²) was used for ANOVA analyses due to the missing data points. The mean time for blood removal was 483 ± 163 seconds (~ 41 ml/minute) for the three aliquots. The first aliquot took 538 ± 134 seconds (~ 37 ml/minute), the second aliquot took 468 ± 160 seconds (~ 43 ml/minute), and the final aliquot took 436 ± 194 seconds (~ 46 ml/minute). The time to fill each aliquot was not statistically distinguishable ($P = 0.068$). The correlation of the amalgamated hemodynamic values obtained during BL and LBNP are presented in Figure 2. Tables 1 and 2 display the mean and range of individual r^2 values of the hemodynamic variables versus CVP and pulse pressure, respectively. The mean and range of individual regression line slope values of hemodynamic variables versus CVP and pulse pressure are presented in Tables 1 and 2 as well. The mean and individual hemodynamic values generated at each stage across the range of CVP and pulse pressure during LBNP and BL are displayed in Figures 3 and 4, respectively. The mean hemodynamic values obtained at each stage during both protocols are presented in Table 3. The mean and range of individual regression line slope values achieved by plotting blood analyte responses against CVP and pulse pressure are displayed in Table 4. The mean blood analyte data obtained at baseline and at protocol termination are presented in Table

5. The mean and individual catecholamine values generated at baseline and at protocol termination plotted against CVP and pulse pressure are displayed in Figure 5.

Central venous pressure. There was a strong correlation for the amalgamated CVP values between BL and LBNP ($r^2 = 0.99$) (Figure 2A).

Heart rate. There was a strong correlation for the amalgamated heart rate values between BL and LBNP ($r^2 = 0.97$) (Figure 2B). Individual r^2 values ($P = 0.371$) and regression line slopes ($P = 0.158$) generated from the relationships between heart rate and CVP from each protocol were statistically similar between BL and LBNP (Table 1). Individual r^2 values ($P = 0.010$) and regression line slopes ($P = 0.024$) produced from the relationships between heart rate and pulse pressure from both protocols were statistically greater in LBNP when compared to BL (Table 2).

Mean arterial pressure. There was a good correlation for the amalgamated MAP values between BL and LBNP ($r^2 = 0.74$) (Figure 2C). Individual r^2 values ($P = 0.007$) and regression line slopes ($P = 0.037$) produced from the relationships between MAP and CVP from each protocol were statistically greater in LBNP when compared to BL (Table 1). Individual r^2 values ($P = 0.902$) and regression line slopes ($P = 0.567$) produced from the relationships between MAP and pulse pressure from each protocol were not statistically similar between BL and LBNP (Table 2).

Pulse Pressure. There was a strong correlation for the amalgamated PP values between BL and LBNP ($r^2 = 0.99$) (Figure 2D). Individual r^2 values ($P = 0.113$) and regression line slopes ($P = 0.105$) calculated from the relationships between PP and CVP from each protocol were statistically similar between BL and LBNP (Table 1).

Arterial oxygen saturation, blood gases, hematocrit, and hemoglobin. Individual r^2

values ($P = 0.733$) and regression line slopes ($P = 0.999$) calculated from the relationships between arterial oxygen saturation and CVP from the LBNP and BL protocols were not distinguishable (Table 1). Individual r^2 values ($P = 0.311$) and regression line slopes ($P = 0.102$) generated from the relationship between arterial oxygen saturation and pulse pressure from each protocol were not statistically distinguishable between BL and LBNP (Table 2). The arterial partial pressure of oxygen, partial pressure of carbon dioxide, and pH responses were similar between BL and LBNP at baseline and protocol termination (Table 5). The regression line slopes for the arterial partial pressure of oxygen, partial pressure of carbon dioxide, and pH were not different between BL and LBNP when the responses were plotted against CVP or pulse pressure ($P > 0.05$). The regression line slopes of hematocrit plotted against CVP and pulse pressure were different between BL and LBNP ($P = 0.002$ and $P < 0.001$, respectively) (Table 4). The regression line slopes of hemoglobin plotted against CVP and pulse pressure were also different between protocols ($P = 0.001$ and $P = 0.027$, respectively) (Table 4).

Stroke volume. There was a strong correlation for the amalgamated stroke volume values between BL and LBNP ($r^2 = 0.98$) (Figure 2E). Individual r^2 values ($P = 0.232$) and regression line slopes ($P = 0.636$) produced from the relationships between stroke volume and CVP from each protocol were statistically similar between BL and LBNP (Table 1). Individual r^2 values ($P = 0.978$) and regression line slopes ($P = 0.922$) obtained from the relationships between stroke volume and pulse pressure from each protocol were statistically similar between BL and LBNP (Table 2).

Cardiac output. There was a good correlation for the amalgamated cardiac output values between BL and LBNP ($r^2 = 0.80$). Individual r^2 values ($P = 0.433$) and regression line slopes ($P = 0.642$) generated from the relationships between cardiac output and CVP from each protocol

were statistically similar between BL and LBNP (Table 1). Individual r^2 values ($P = 0.945$) and regression line slopes ($P = 0.121$) produced from the relationships between cardiac output and pulse pressure from each protocol were statistically similar between BL and LBNP (Table 2).

Oxygen delivery. The regression line slope generated from the relationship between oxygen delivery and CVP during LBNP was not statistically different from the slope obtained during BL ($P = 0.164$) (Table 4). The regression line slope produced from the relationship between oxygen delivery and pulse pressure was also statistically indistinguishable between LBNP and BL ($P = 0.064$) (Table 4).

Total peripheral resistance. There was a modest correlation for the amalgamated total peripheral resistance values between BL and LBNP ($r^2 = 0.53$) (Figure 2F). Individual r^2 values ($P = 0.907$) and regression line slopes ($P = 0.124$) produced from the relationships between total peripheral resistance and CVP from each protocol were statistically similar between BL and LBNP (Table 1). Individual r^2 values ($P = 0.364$) and regression line slopes ($P = 0.849$) generated from the relationships between stroke volume and pulse pressure from each protocol were statistically similar between BL and LBNP (Table 2).

Catecholamines. The regression line slope generated from the relationship between norepinephrine and CVP during LBNP was steeper than the slope obtained during BL ($P = 0.011$) (Table 4). The regression line slopes produced from the relationships between norepinephrine and pulse pressure from each of the protocols were not statistically distinguishable ($P = 0.129$) (Table 4). The regression line slope produced from the relationship between epinephrine and CVP ($P = 0.816$) and between epinephrine and pulse pressure ($P = 0.470$) were not different between protocols.

Arginine vasopressin. The regression line slopes obtained from plotting arginine

vasopressin against CVP were not statistically distinguishable between BL and LBNP ($P = 0.152$) (Table 4). Additionally, the regression line slopes generated between arginine vasopressin and pulse pressure were not different between protocols ($P = 0.936$) (Table 4).

DISCUSSION

The overarching results of this investigation indicate that LBNP elicits similar hemodynamic stimulus-response relationships as BL throughout the ranges of CVP and pulse pressure that were attained. That is, with the exception of heart rate and MAP, the relationship between indices of central blood volume (i.e. CVP and pulse pressure) and hemodynamic responses produced by stepwise decreases in circulating blood volume were mimicked by progressive reductions in LBNP. This is demonstrated by the similar response trajectories across the wide range of CVP and pulse pressures that were achieved for multiple hemodynamic variables between the two protocols. Therefore, our results provide the first direct comparison of data from human subjects who have undergone more than 450 ml of BL and LBNP. Furthermore, these data support our hypothesis that LBNP models multiple hemodynamic responses induced by hemorrhage.

Heart rate during the LBNP and BL protocols followed similar trajectories throughout the range of CVP. Rea et al. (30) found that heart rate increased 3 bpm following only 450 ml of BL (reduced CVP by ~ 2.4 mmHg), whereas heart rate remained unchanged during 15 mmHg of LBNP (reduced CVP by ~ 3.8 mmHg). These small changes in heart rate following a modest volume of BL suggest that heart rate might respond differently to BL when compared to LBNP. As a clinical perspective, an elevation in heart rate caused by hemorrhage is a tool used to assess patient status in trauma situations. However, the results presented here reinforce the idea that tachycardic heart rates may not necessarily reflect the severity of BL or predict impending hemodynamic collapse (8, 34). Removing up to 17% of total blood volume and reducing CVP to as low as -2 mmHg, did not elicit a heart rate over 100 bpm in any subject during the BL protocol. Furthermore, only one subject achieved a heart rate above 100 bpm during the last two

stages of the LBNP protocol. In this context, an increase in total peripheral resistance appears to be a main contributor to the defense of MAP during central hypovolemia. Our data support this idea as we observed an increase in total peripheral resistance while MAP remained unchanged during the first two stages of the LBNP and BL protocols. Additionally, it has been shown that muscle sympathetic nerve activity increases while heart rate and MAP remain stable during low levels of LBNP (30).

Although MAP correlated well between LBNP and BL, the response trajectories across a wide range of CVP differed statistically between the protocols. MAP was statistically unaltered throughout the early stages of both BL and LBNP and was only lower than baseline during the final stage of both protocols. This observation is consistent with previous reports which indicate that MAP is well-defended in spite of progressive reductions in central blood volume (6, 10). The well-defended MAP during the BL protocol also highlights the concept that using MAP to monitor patients during hemorrhage may not provide accurate information regarding hemodynamic stability (10). In this context, of the three subjects who did not complete the entire BL protocol due to pre-syncope symptoms or syncope did not exhibit unusually low MAP. The final MAP prior to protocol termination in these subjects was 75 mmHg following 333 ml of BL, and 72 and 85 mmHg following 667 ml of BL. Furthermore, MAP was either unchanged or slightly increased following 1000 ml of BL in 5 subjects.

Importantly, stroke volume was well correlated between LBNP and BL and the stroke volume response trajectories across the range of CVP were remarkably similar between the LBNP and BL protocol. Reductions in stroke volume are an early indicator that central blood volume has decreased and stroke volume declines during progressive reductions in LBNP (4, 5, 7, 20, 22, 29, 31, 32). However, previous studies have not compared stroke volume during

graded LBNP to graded BL in humans. In baboons, decreases in stroke volume were nearly identical during LBNP and BL across an extensive range of CVP (23). Our results in humans reinforce the baboon data indicating that stroke volume during graded LBNP accurately models the changes in stroke volume obtained during graded BL. Additionally, aside from CVP, stroke volume was the first hemodynamic variable measured that was statistically different from baseline following 667 ml of BL. In this context, stroke volume also had the greatest decrease from baseline to protocol termination in the subjects who were unable to complete LBNP and BL protocols. In these non-finishers, stroke volume fell by 10-36% before LBNP protocol termination and stroke volume decreased by 16-25% prior to the cessation of the BL protocol. Therefore, these data support the idea that monitoring stroke volume during BL provides an accurate reflection of decreases in blood volume (26) and tracking stroke volume might provide caregivers vital hemodynamic information that could be used to prevent cardiovascular collapse.

We found statistically different hematocrit and hemoglobin responses to the LBNP and BL protocols. These findings are similar to those observed in anesthetized baboons (23). The reduction in hematocrit and hemoglobin during BL represents a shift of fluid from the extravascular to the intravascular space to counteract the reduction in circulating blood volume (1, 25, 27). Whereas the increase in hematocrit and hemoglobin during LBNP is likely due to a plasma volume shift from the intravascular to extravascular space in the lower body as a result of the large pressure gradient which occurs during LBNP. The differences in hemoglobin, hematocrit, and cardiac output between the protocols generated a lower calculated oxygen delivery during LBNP when compared to BL. However, it is doubtful that the disparities in oxygen delivery caused significant physiological changes in tissue oxygenation during LBNP and BL. This is reinforced by our observation that blood pH and the partial pressure of carbon

dioxide were unaffected in both protocols.

The circulating catecholamine responses in our LBNP and BL protocols differ from those obtained in baboons (23). We did not observe a statistically significant increase in circulating norepinephrine during the BL protocol but we did observe an increase during LBNP. The mean norepinephrine response in the subjects who completed the BL protocol (65% increase) was nearly 100% lower than the mean values obtained during the LBNP protocol (162% increase). Interestingly, the three subjects that did not complete the BL protocol had abnormally low norepinephrine responses (change from baseline values were -47%, -15%, and 7%). Regardless of the statistically similar epinephrine responses, it is plausible that our BL protocol did not activate the sympathetic nervous system to the same extent as the LBNP protocol. This finding is consistent with our observation that total peripheral resistance was consistently lower during BL when compared to the LBNP protocol.

Despite lower CVP and pulse pressure during the last LBNP stage when compared to the final BL stage, we observed statistically similar arginine vasopressin responses to both protocols. The increase in arginine vasopressin in both protocols is not surprising (1, 2, 11, 18, 24, 37). However, when baboons underwent LBNP and BL protocols and CVP and pulse pressure were matched between protocols, the arginine vasopressin response was lower during LBNP when compared to BL (23). It was speculated that arginine vasopressin may be differentially released between the protocols possibly due to a decrease in oxygen delivery during BL as a result of decreases in hematocrit, hemoglobin, and central venous oxygen saturation (23). Our data contrast this idea as the arginine vasopressin response was statistically similar between LBNP and BL even though oxygen delivery was greater in BL when compared to LBNP. Previous reports have suggested that arginine vasopressin is associated with pre-syncope symptoms (2, 11,

18). Therefore, we examined the six individual protocols (3 LBNP and 3 BL) that were not completed and found that five of the six arginine vasopressin responses were considerably large. The mean increase of arginine vasopressin in these individual protocols was nearly 5 times the mean value obtained from the subjects that completed the protocols. In this context, arginine vasopressin might be an additional marker that can be used in conjunction with the monitoring of other hemodynamic variables, like stroke volume, that would give caregivers insight on patient stability during hemorrhagic trauma.

Limitations

Several limitations pertain to our study. First, we removed blood volume using three equal aliquots that were not based on a percentage of total blood volume. LBNP protocols are also not based on body size and it is difficult to measure the volume of blood that shifts from the thorax to the capacitance vessels in the legs during LBNP and this volume likely varies from person to person. In this context, LBNP might substantially impede the mobilization of sequestered blood in the leg capacitance vessels to the central circulation via changes in intrathoracic pressure during breathing when compared with BL. That is, the respiratory pump might lose its effectiveness in aiding venous return for a given reduction in central blood volume during LBNP; whereas changes in intrathoracic pressures during BL are not competing against lower body suction for blood volume. This effect might contribute to the divergent stimulus-response trajectories between LBNP and BL in some hemodynamic variables. The physiological consequence of this potential sequestration effect during LBNP needs to be compared with absolute reductions in blood volume during BL to fully elucidate the potential impact it has on the respiratory pump. Second, we did not take all subjects in both protocols to tolerance due to subject safety. Therefore, it remains unclear if the response trajectories remain similar between

LBNP and BL at lower levels of central hypovolemia. Third, we were unable to match the rate of negative pressure change during the LBNP protocol to the rate of blood removal during BL because we randomized the order of the protocols. This temporal difference between protocols may have differentially influenced hemodynamic adjustments to changes in central blood volume during the BL protocol when compared to the LBNP protocol. However, we allowed three minutes after progressing to the next LBNP stage and following the removal of each aliquot of blood to reach a stable hemodynamic state prior to data analysis. Fourth, we only collected blood at baseline and at the termination of each protocol. Therefore, we cannot discern if the blood analyte responses are linear throughout the CVP and pulse pressures obtained during each protocol. Fifth, we did not test women. Due to a lower total blood volume in women, removing 1000 ml of blood represents a greater percentage of total blood volume and thus increases the risk of cardiovascular collapse. Interestingly however; we may have observed differential responses between men and women because women typically have a lower orthostatic stress tolerance than men (17) and hemodynamic responses to orthostatic stress are different between sexes (19). Furthermore, young women appear to regulate blood pressure differently than young men (21), which may influence hemodynamic responses to central hypovolemia.

CONCLUSIONS

We observed striking similarities between LBNP and BL in the stimulus-response relationships of central venous pressure and pulse pressure to hemodynamic responses. As such, LBNP mimics the trajectories of the hemodynamic responses observed during BL across a significant range of central venous pressure and pulse pressure in humans. Therefore, our data support the hypothesis that LBNP adequately reflects the hemodynamic responses observed during BL.

ACKNOWLEDGMENTS

We would like to thank the subjects for their participation in this study. We also thank Margaret McGill-Zimny and David Warren for their assistance on the blood loss protocol. This study was funded by U.S. Army MRMC Combat Casualty Care Research Program Grant # W81XWH-11-1-0823. BDJ was supported by American Heart Association Midwest Affiliate 13POST14380027. NVH was supported by Dutch Heart Foundation E. Dekker stipend 2012SB013.

DISCLOSURES

The authors have no conflicts of interest to report.

REFERENCES

1. **Arnauld E, Czernichow P, Fumoux F, and Vincent J-D.** The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (*Macaca mulatta*). *Pflügers Archiv* 371: 193-200, 1977.
2. **Baylis PH, Stockley RA, and Heath DA.** Influence of lower body negative pressure upon arginine vasopressin release. *Clinical endocrinology* 9: 89-95, 1978.
3. **Champion HR, Bellamy RF, Roberts CP, and Leppaniemi A.** A Profile of Combat Injury. *Journal of Trauma and Acute Care Surgery* 54: 2003.
4. **Convertino VA, Cooke WH, and Holcomb JB.** Arterial pulse pressure and its association with reduced stroke volume during progressive central hypovolemia. *The Journal of Trauma* 61: 629 - 634, 2006.
5. **Convertino VA, Grudic G, Mulligan J, and Moulton S.** Estimation of individual-specific progression to impending cardiovascular instability using arterial waveforms. *Journal of Applied Physiology* 115: 1196-1202, 2013.
6. **Convertino VA, Moulton SL, Grudic GZ, Rickards CA, Hinojosa-Laborde C, Gerhardt RT, Blackburne LH, and Ryan KL.** Use of advanced machine-learning techniques for noninvasive monitoring of hemorrhage. *The Journal of Trauma and Acute Care Surgery* 71: S25-S32, 2011.
7. **Convertino VA, Rickards CA, Lurie KG, and Ryan KL.** Hyperventilation in Response to Progressive Reduction in Central Blood Volume to Near Syncope. *Aviation, space, and environmental medicine* 80: 1012-1017, 2009.
8. **Convertino VA, Rickards CA, and Ryan KL.** Autonomic mechanisms associated with heart rate and vasoconstrictor reserves. *Clin Auton Res* 22: 123-130, 2012.

9. **Convertino VA, Ryan KL, Rickards CA, Cooke WH, Idris AH, Metzger A, Holcomb JB, Adams BD, and Lurie KG.** Inspiratory resistance maintains arterial pressure during central hypovolemia: Implications for treatment of patients with severe hemorrhage. *Critical Care Medicine* 35: 2007.
10. **Convertino VA, Ryan KL, Rickards CA, Salinas J, McManus JG, Cooke WH, and Holcomb JB.** Physiological and medical monitoring for en route care of combat casualties. *The Journal of Trauma and Acute Care Surgery* 64: S342-S353, 2008.
11. **Convertino VA, and Sather TM.** Vasoactive neuroendocrine responses associated with tolerance to lower body negative pressure in humans. *Clinical Physiology* 20: 177-184, 2000.
12. **Cooke WH, Ryan KL, and Convertino VA.** Lower body negative pressure as a model to study progression to acute hemorrhagic shock in humans. *Journal of Applied Physiology* 96: 1249-1261, 2004.
13. **Cvirn G, Schlagenhauf A, Leschnik B, Koestenberger M, Roessler A, Jantscher A, Vrecko K, Juergens G, Hinghofer-Szalkay H, and Goswami N.** Coagulation Changes during Presyncope and Recovery. *PloS one* 7: e42221, 2012.
14. **Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, Mallett O, Zubko T, Oetjen-Gerdes L, Rasmussen TE, Butler FK, Kotwal RS, Holcomb JB, Wade C, Champion H, Lawnick M, Moores L, and Blackbourne LH.** Death on the battlefield (2001-2011): implications for the future of combat casualty care. *The Journal of Trauma and Acute Care Surgery* 73: S431-437, 2012.
15. **Engelke KA, Doerr DF, Crandall CG, and Convertino VA.** Application of acute maximal exercise to protect orthostatic tolerance after simulated microgravity. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* 271: R837-R847, 1996.

16. **Evans J, Wessem KP, McDougall D, Lee K, Lyons T, and Balogh Z.** Epidemiology of Traumatic Deaths: Comprehensive Population-Based Assessment. *World J Surg* 34: 158-163, 2010.
17. **Franke WD, Johnson CP, Steinkamp JA, Wang R, and Halliwill JR.** Cardiovascular and autonomic responses to lower body negative pressure. *Clin Auton Res* 13: 36-44, 2003.
18. **Goldsmith SR, Francis GS, Cowley AW, and Cohn JN.** Response of vasopressin and norepinephrine to lower body negative pressure in humans. *American Journal of Physiology - Heart and Circulatory Physiology* 243: H970-H973, 1982.
19. **Gotshall RW, Tsai P-F, and Frey MA.** Gender-based differences in the cardiovascular response to standing. *Aviation, space, and environmental medicine* 62: 855, 1991.
20. **Hanson JM, Van Hoeyweghen R, Kirkman E, Thomas A, and Horan MA.** Use of Stroke Distance in the Early Detection of Simulated Blood Loss. *Journal of Trauma and Acute Care Surgery* 44: 1998.
21. **Hart EC, Charkoudian N, Wallin BG, Curry TB, Eisenach J, and Joyner MJ.** Sex and ageing differences in resting arterial pressure regulation: the role of the β -adrenergic receptors. *The Journal of Physiology* 589: 5285-5297, 2011.
22. **Hinojosa-Laborde C, Rickards C, Ryan K, and Convertino V.** Heart rate variability during simulated hemorrhage with lower body negative pressure in high and low tolerant subjects. *Frontiers in Physiology* 2: 2011.
23. **Hinojosa-Laborde C, Shade RE, Muniz GW, Bauer C, Goei KA, Pidcoke HF, Chung KK, Cap AP, and Convertino VA.** Validation of Lower Body Negative Pressure as an Experimental Model of Hemorrhage. *Journal of Applied Physiology* 2013.
24. **Jacobsen J, Søfelt S, Sheikh S, Warberg J, and Secher NH.** Cardiovascular and

endocrine responses to haemorrhage in the pig. *Acta Physiologica Scandinavica* 138: 167-173, 1990.

25. **Kashimoto S, Doursout M-F, Hartley C, and Chelly JE.** Effects of thiopental and ketamine on cardiac function during moderate hemorrhage in chronically instrumented rats. *Journal of Cardiovascular Pharmacology* 21: 829-833, 1993.

26. **Leonetti P, Audat F, Girard A, Laude D, Lefrère F, and Elghozi J-L.** Stroke volume monitored by modeling flow from finger arterial pressure waves mirrors blood volume withdrawn by phlebotomy. *Clin Auton Res* 14: 176-181, 2004.

27. **McDonough KH, Giaimo M, Quinn M, and Miller H.** Intrinsic myocardial function in hemorrhagic shock. *Shock* 11: 205-210, 1999.

28. **Morris MJ, Russell AE, Kapoor V, Cain MD, Elliott JM, West MJ, Wing LMH, and Chalmers JP.** Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. *Journal of the autonomic nervous system* 17: 143-149, 1986.

29. **Norsk P, Ellegaard P, Videbaek R, Stadeager C, Jessen F, Johansen LB, Kristensen MS, Kamegai M, Warberg J, and Christensen NJ.** Arterial pulse pressure and vasopressin release in humans during lower body negative pressure. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* 264: R1024-R1030, 1993.

30. **Rea RF, Hamdan M, Clary MP, Randels MJ, Dayton PJ, and Strauss RG.** Comparison of muscle sympathetic responses to hemorrhage and lower body negative pressure in humans. *Journal of Applied Physiology* 70: 1401-1405, 1991.

31. **Rickards CA, Ryan KL, Cooke WH, and Convertino VA.** Tolerance to central hypovolemia: the influence of oscillations in arterial pressure and cerebral blood velocity. *Journal of Applied Physiology* 111: 1048-1058, 2011.

32. **Ryan KL, Cooke WH, Rickards CA, Lurie KG, and Convertino VA.** Breathing through an inspiratory threshold device improves stroke volume during central hypovolemia in humans. *Journal of Applied Physiology* 104: 1402-1409, 2008.
33. **Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, and Pons PT.** Epidemiology of Trauma Deaths: A Reassessment. *Journal of Trauma and Acute Care Surgery* 38: 1995.
34. **Schafer K, Van Sickle C, Hinojosa-Laborde C, and Convertino VA.** Physiologic mechanisms underlying the failure of the "shock index" as a tool for accurate assessment of patient status during progressive simulated hemorrhage. *Journal of Trauma and Acute Care Surgery* 75: 2013.
35. **Søreide K, Krüger A, Vårdal A, Ellingsen C, Søreide E, and Lossius H.** Epidemiology and Contemporary Patterns of Trauma Deaths: Changing Place, Similar Pace, Older Face. *World J Surg* 31: 2092-2103, 2007.
36. **Thompson CA, Tatro DL, Ludwig DA, and Convertino VA.** Baroreflex responses to acute changes in blood volume in humans. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology* 259: R792-R798, 1990.
37. **Wang BC, Sundet WD, Hakumaki MO, and Goetz KL.** Vasopressin and renin responses to hemorrhage in conscious, cardiac-denervated dogs. *American Journal of Physiology-Heart and Circulatory Physiology* 245: H399-H405, 1983.
38. **Wesseling KH, Jansen JR, Settels JJ, and Schreuder JJ.** Computation of aortic flow from pressure in humans using a nonlinear, three-element model. *Journal of Applied Physiology* 74: 2566-2573, 1993.

Table 1. Mean and range of individual r^2 values and the mean and range of individual regression line slope values of hemodynamic variables versus central venous pressure.

		r^2	r^2 range	Slope	Slope range
Heart rate					
	LBNP	0.67	0.14 - 0.95	-2.42	-4.58 - -0.46
	BL	0.54	0.02 - 0.98	-1.53	-5.29 - 0.12
MAP					
	LBNP	0.68	0.23 - 0.99	0.93	0.08 - 3.48
	BL	0.35†	<0.01 - 0.66	0.13†	-1.30 - 2.12
Pulse Pressure					
	LBNP	0.72	0.01 - 0.97	1.81	0.03 - 4.37
	BL	0.49	<0.01 - 0.92	1.23	0.09 - 3.63
S_aO_2					
	LBNP	0.52	0.03 - 0.95	-0.42	-0.28 - 0.23
	BL	0.46	0.01 - 0.98	-0.04	-0.68 - 0.32
Stroke Volume					
	LBNP	0.85	0.44 - 0.99	3.69	1.86 - 5.26
	BL	0.73	<0.01 - 0.93	3.59	0.25 - 5.74
Cardiac Output					
	LBNP	0.68	0.18 - 0.99	0.10	-0.02 - 0.24
	BL	0.61	<0.01 - 0.98	0.10	-0.13 - 0.31
TPR					
	LBNP	0.51	0.24 - 0.99	-0.26	-0.63 - 0.17
	BL	0.53	0.02 - 0.99	0.07	0.75 - 0.99

LBNP = lower body negative pressure; BL = blood loss; MAP = mean arterial pressure; S_aO_2 = arterial oxygen saturation; TPR = total peripheral resistance.

†Different from lower body negative pressure ($P < 0.05$).

Table 2. Mean and range of individual r^2 values and the mean and range of individual regression line slope values of hemodynamic variables versus pulse pressure.

		r^2	r^2 range	Slope	Slope range
Heart rate					
	LBNP	0.86	0.57 - 0.98	-1.85	-6.12 - -0.38
	BL	0.57†	0.03 - 0.99	-0.46†	-2.19 - 0.76
MAP					
	LBNP	0.70	0.04 - 1.00	0.43	-0.29 - 1.95
	BL	0.43	<0.01 - 0.66	0.67	-0.20 - 1.52
S _a O ₂					
	LBNP	0.59	<0.01 - 0.99	0.08	-0.14 - 1.05
	BL	0.42	<0.01 - 0.99	-0.01	-0.40 - 0.31
Stroke Volume					
	LBNP	0.86	0.49 - 0.99	2.76	1.16 - 8.94
	BL	0.86	0.29 - 1.00	2.17	1.02 - 4.74
Cardiac Output					
	LBNP	0.69	<0.01 - 0.96	0.06	<0.01 - 0.11
	BL	0.66	0.03 - 0.99	0.09	<-0.01 - 0.22
TPR					
	LBNP	0.52	<0.01 - 0.96	-0.19	-0.68 - 0.04
	BL	0.64	<0.01 - 0.99	-0.18	-0.47 - 0.12

LBNP = lower body negative pressure; BL = blood loss; MAP = mean arterial pressure; S_aO₂ = arterial oxygen saturation; TPR = total peripheral resistance.

†Different from lower body negative pressure (P < 0.05).

Table 3. Hemodynamic responses during each stage of lower body negative pressure and blood loss.

		Baseline	Stage 1	Stage 2	Stage 3
CVP (mmHg)	LBNP	7.1 ± 0.9	2.6 ± 0.9 ^a	0.8 ± 0.8 ^{ab}	-0.6 ± 0.8 ^{abc}
	BL	5.9 ± 0.8	3.6 ± 0.9 ^a	2.2 ± 1.1 ^{abd}	1.2 ± 1.1 ^{abd}
Heart rate (bpm)	LBNP	62 ± 2.8	64 ± 3.8	71 ± 5.2 ^{ab}	83 ± 6.3 ^{abc}
	BL	59 ± 3.4	60 ± 3.0	63 ± 2.8 ^d	67 ± 3.5 ^{ad}
MAP (mmHg)	LBNP	95.1 ± 3.2	93.0 ± 3.3	92.3 ± 3.3	87.3 ± 4.0 ^e
	BL	91.4 ± 2.7	91.0 ± 2.4	90.3 ± 3.0	89.2 ± 2.7 ^e
PP (mmHg)	LBNP	66.2 ± 4.3	62.2 ± 4.3	57.4 ± 3.8 ^a	48.7 ± 4.9 ^{abc}
	BL	63.8 ± 3.9	61.9 ± 3.4	58.6 ± 4.1	55.7 ± 4.1 ^{ad}
S _a O ₂ (%)	LBNP	96.5 ± 0.7	97.0 ± 0.5	96.9 ± 0.4	96.9 ± 0.3
	BL	97.5 ± 0.3	97.5 ± 0.3	97.4 ± 0.3	98.1 ± 0.4 ^d
SV (ml/beat)	LBNP	82.8 ± 3.1	72.8 ± 3.0 ^a	63.9 ± 3.4 ^{ab}	50.8 ± 3.7 ^{abc}
	BL	88.8 ± 3.1 ^d	83.8 ± 2.6 ^d	77.6 ± 3.4 ^{ad}	70.6 ± 4.0 ^{abcd}
CO (l/min)	LBNP	5.2 ± 0.4	4.6 ± 0.2	4.5 ± 0.3 ^e	4.1 ± 0.2 ^{ef}
	BL ^d	5.3 ± 0.4	5.1 ± 0.3	4.8 ± 0.2 ^e	4.7 ± 0.2 ^{ef}
TPR (mmHg/l/min)	LBNP	18.9 ± 0.9	20.4 ± 0.8	21.0 ± 1.1 ^e	21.6 ± 1.0 ^e
	BL ^d	17.9 ± 1.2	18.2 ± 1.0	18.9 ± 0.8 ^e	19.3 ± 0.7 ^e

LBNP = lower body negative pressure; Stage 1 = 15 mmHg, Stage 2 = 30 mmHg, Stage 3 = 45 mmHg.

BL = blood loss; Stage 1 = 333 ml, Stage 2 = 667 ml, Stage 3 = 1000 ml.

CVP = central venous pressure; MAP = mean arterial pressure; PP = pulse pressure; S_aO₂ = arterial oxygen saturation; SV = stroke volume; CO = cardiac output; TPR = total peripheral resistance.

Values are means ± standard error, n = 8.

^aDifferent from Baseline (P < 0.05).

^bDifferent from Stage 1 (P < 0.05).

^cDifferent from Stage 2 (P < 0.05).

^dDifferent from lower body negative pressure (P < 0.05).

^eStage main effect, different from Baseline (P < 0.05).

^fStage main effect, different from Stage 1 (P = 0.025).

Table 4. Mean and range of individual regression line slope values of blood analyte and oxygen delivery responses versus central venous pressure and pulse pressure.

		<u>Central Venous Pressure</u>		<u>Pulse Pressure</u>	
		Slope	Slope range	Slope	Slope range
Norepinephrine					
	LBNP	-27.8	-80.7 - 0.6	-30.3	-178.1 - 0.2
	BL	-8.7†	-32.7 - 39.5	-5.1	-42.7 - 45.0
Epinephrine					
	LBNP	-13.5	-48.3 - 0.0	-8.9	-24.9 - 0.0
	BL	-14.5	-36.3 - -1.2	-1.6	-12.1 - 45.0
Hematocrit					
	LBNP	-0.22	-0.58 - 0.07	-0.50	-4.98 - 0.08
	BL	0.24†	-0.33 - 1.18	0.04†	-1.17 - 0.73
Hemoglobin					
	LBNP	-0.07	-0.18 - 0.05	-0.16	-1.53 - 0.02
	BL	0.08†	-0.17 - 0.30	-0.02†	-0.45 - 0.11
Arginine					
Vasopressin					
	LBNP	-2.1	-7.8 - 0.1	-1.0	-3.2 - 0.2
	BL	-4.5	-20.8 - 0.6	-0.9	-3.6 - 0.9
Oxygen Delivery					
	LBNP	17.3	-10.6 - 74.2	1.8	-91.4 - 27.8
	BL	38.5	-25.8 - 137.3	10.2	-142.8 - 58.2

LBNP = lower body negative pressure; BL = blood loss.

†Different from lower body negative pressure ($P < 0.05$).

Table 5. Blood analyte and oxygen delivery responses at baseline and the termination of lower body negative pressure and blood loss protocols.

		Baseline	Termination
Norepinephrine (pg/ml)			
	LBNP	148 ± 20	354 ± 44 [^]
	BL	155 ± 22	211 ± 29 [†]
Epinephrine (pg/ml)			
	LBNP	53 ± 7	144 ± 30*
	BL	49 ± 7	103 ± 19*
Hematocrit (%)			
	LBNP	40.8 ± 0.8	42.4 ± 0.8 [^]
	BL	41.1 ± 0.8	40.3 ± 0.9 ^{^†}
Hemoglobin (g/dl)			
	LBNP	14.2 ± 0.4	14.7 ± 0.4 [^]
	BL	14.3 ± 0.4	14.0 ± 0.4 ^{^†}
Oxygen (mmHg)			
	LBNP	99.5 ± 2.9	97.8 ± 3.1
	BL	105.1 ± 3.5	103.8 ± 2.7
Carbon Dioxide (mmHg)			
	LBNP	42.1 ± 0.9	41.7 ± 1.0
	BL	41.5 ± 0.6	41.0 ± 0.7
pH			
	LBNP	7.42 ± 0.01	7.41 ± 0.01
	BL	7.42 ± 0.01	7.42 ± 0.01
Bicarbonate (mmol/l)			
	LBNP	26.2 ± 0.2	25.8 ± 0.4*
	BL	26.2 ± 0.3	25.8 ± 0.3*
Arginine Vasopressin (pg/ml)			
	LBNP	2.8 ± 0.7	19.1 ± 6.2*
	BL	3.4 ± 0.7	13.5 ± 4.0*
Oxygen Delivery (ml/minute)			
	LBNP	948 ± 57	809 ± 32*
	BL [†]	1036 ± 59	926 ± 37*

LBNP = lower body negative pressure; BL = blood loss.

Values are means ± standard error, n = 12.

*Stage main effect, different from Baseline (P < 0.05).

[^]Different from Baseline (P < 0.05).

[†]Different from lower body negative pressure (P < 0.05).

Figure 1. Timeline of the lower body negative pressure and blood loss protocols. The order of the protocols was randomized. When the lower body negative pressure protocol was performed first, 45 minutes of quiet rest was given between protocols to ensure hemodynamic variables returned to baseline. To allow for the reinfusion of removed blood, 75 minutes of quiet resting was given to allow for hemodynamic variables to return to baseline between protocols when blood loss occurred first. Arterial blood was drawn at baseline and during the last stage of each protocol for blood gases, pH, bicarbonate, catecholamines, hematocrit, hemoglobin, and arginine vasopressin.

Figure 2. Correlation of the amalgamated hemodynamic values obtained during lower body negative pressure versus blood loss. BL = blood loss; LBNP = lower body negative pressure.

Figure 3. The mean and individual hemodynamic values obtained at each stage across the range of central venous pressures during the lower body negative pressure and blood loss protocols.

Figure 4. The mean and individual hemodynamic values obtained at each stage across the range of pulse pressures during the lower body negative pressure and blood loss protocols.

Figure 5. The mean and individual catecholamine values obtained at baseline and protocol termination across the range of central venous pressures and pulse pressures during the lower body negative pressure and blood loss protocols.

Figure 1.




Figure 2.




Figure 3.




Figure 4.




Figure 5.

